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CHAPTER 1 
INTRODUCTION 
L i s t of abbrev iat ions. 
AU 
ECar 
EIA 
GLA 
GLU 
HPLC 
K1 
4 
КЗ 
KH2 
КО 
NT 
PIVKA 
PIVKA-II · 
PPSB 
PT 
PTT 
TT 
X
a
PC 
: arbitrary units 
Echis Carinatus venom 
enzyme immuno assay 
gamma-carboxy glutamic acid 
• glutamic acid 
high performance liquid chromatography 
phyloquinone 
menaquinone 
menadione 
vitamin К hydroxyquinone 
vitamin K-2,3-epoxide 
Normotest 
protein induced by vitamin К absence 
des-carboxylated prothrombin 
four coagulation-factors concentrate 
prothrombin time 
partial thromboplastin time 
thrombotest 
active factor X, phospholipid, calcium 
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It has already been established for over 40 years that vitamin К admi­
nistration to neonates is effective in the prevention of bleeding due 
to vitamin K-deficiency (1, 2). Initially vitamin К was administered 
daily in high doses of 10 mg vitamin K3 (menadione), a synthetic ana-
logon of the natural K-vitamins (3). In 1955 the less toxic vitamin K-| 
(phyloquinone), suited for parenteral administration, became commerci­
ally available and parenteral injection of 1 mg vitamin Κι at birth 
was recommended for prophylaxis of vitamin К dependent haemorrhage 
(4). 
In the U.S.A. vitamin К prophylaxis is a routine, whereas in most Eu­
ropean countries prophylactic administration of vitamin К after birth 
is performed only in a selected group of newborns (prematures, infants 
after caesarean section, forcipal extraction). 
At present a controversy exists about the value of prophylactic vita­
min К administration to normal newborns (5-14). 
A review is presented about the current knowledge of vitamin K, its 
role in coagulation, its clinical importance in infancy and the cur­
rent controversies surrounding its prophylactic administration. 
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1.1 HAEMOSTASIS 
A patient with a haemorrhagic or thrombotic disorder represents a 
complex diagnostic and therapeutic problem. The physician should un­
derstand how the hemostatic mechanisms operate under normal physiolo­
gical conditions. The very complex and highly integrated mechanism in­
volved in hemostasis and thrombosis-prevention are presented in figure 
1-1. The system is composed of blood-vessels, platelets, coagulation 
factors, inhibitors and the fibrinolytic system. To stop bleeding from 
an injured vessel the first step is the formation of a platelet plug, 
which is the primary haemostatic mechanism, this is followed by the 
secondary haemostatic mechanism: the fibrin formation. Inhibitor sys­
tems and fibrinolysis are required to limit the extension of the clot. 
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Figure 1-1. Secondary haemostatic mechanism: f i b r i n c l o t format ion. 
1.2 STRUCTURE AND PROPERTIES OF VITAMIN К 
Vitamin К-) (phyloquinone) and vitamin «2 (menaquinone) are present 
in nature (figure 2). Vitamin K-) is produced by plants, vitamin K2 by 
bacteria. Both are highly apolar. Many homologues of vitamin «2 exist, 
which vary as regards the number of isoprene units in their polyprenyl 
side-chain. 
Besides vitamin K-j and the homologues of K2, which occur in natural 
form, synthetic vitamin К homologues were produced, one of these being 
menadione (K3) (Fig. 1-2). The water soluble menadione is less effec­
tive and more toxic; it was reported to cause jaundice due to 
haemolysis and inhibition of the conjugation of bilirubin to the 
glucuronide in the newborn (15). 
Figure 1-2. Vitamin К homologues. 
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Figure 1-3. The vitamin К cycle. GLU, glutamic acid; GLA, gammacarboxy 
glutamic acid; KH2, vitamin К hydroxyquinone; КО, vitamin 
K-2,3-epoxide. 
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1.3 BIOLOGICAL FUNCTION OF VITAMIN К 
Vitamin К is required for the modification and activation of a num­
ber of important proteins, among them the coagulation factors II, VII, 
IX and X and the coagulation inhibitors protein С and protein S (16). 
The specific action of vitamin К is the posttranslational carboxyla­
tion of glutamic acid residues on the amino-terminal part of the vita­
min К dependent proteins (17). The vitamin К dependent carboxylation 
reaction occurs in the rough endoplasmatic reticulum of the hepatocy-
te. The gamma-carboxy-glutamic acid residues provide these proteins 
with unique calcium and phospholipid binding properties. Des-carboxy-
lated proteins, the so called PIVKAs (Proteins Induced by Vitamin К 
Absence) are functionally defective. 
Vitamin К is first reduced to vitamin К hydroquinone (KH2) in the pre­
sence of NADH or NADPH and subsequently oxidized to vitamin K-2,3-epo-
xide (КО). This oxidation is connected with the carboxylation reaction 
in which gamma-carboxy-glutamic acid is formed. Subsequently vitamin 
K-2,3-epoxide is converted back into natural vitamin К by the enzyme 
epoxide-reductase in the presence of un unknown substrate (17). The 
vitamin К cycle is depicted in figure 1-3. 
1.4 SOURCES OF VITAMIN К IN INFANCY 
Information about dietary requirements and turnover of vitamin К is 
generally much less precise than for the other fat-soluble vitamins. 
Even the fundamental question of the relative importance of the diet 
or intestinal microflora in providing the body's requirement of vita­
min К still remains to be answered (IB). 
At birth the vitamin К status of the human neonate is precarious, and 
some infants are deficient at birth. The lack of storage of vitamin К 
in the neonate may be the result of the placental barrier to vitamin К 
(12, 19). The diet is an important source of vitamin К immediately af­
ter birth, while the gut is still sterile. The dietary content of vi­
tamin Ki varies with different forms of feeding. Human milk contains 
an average level of 2.1 ¿Jg/L vitanin Ki (20). 
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The content of vitamin K·) in breast-milk is influenced by the diet of 
the mother and fluctuations are observed during the day and from day 
to day (21). A difference is also found between 'foremilk' and 
'hindmilk' (21). Commercial formulas in the Netherlands contain at 
least 50 jjg/L vitamin K. Vegetables are in rich vitamin К content (22) 
as shown in table I-1. 
Vitamin К ^g/100 g 
Cow's milk 
Cheese 
Butter 
Eggs 
Meat 
-beef and veal 
-ham 
-bacon 
-cow's liver 
Fruit 
-appeljuice 
-orange 
-banana 
-grapes 
-peach 
Cereales 
-rice 
-maize 
-wheat 
-wheaten bread 
3 
35 
30 
11 
7 
15 
46 
93 
1 
1 
2 
6 
θ 
-
5 
17 
4 
Vegetables 
-potato 
-tomato 
-carrot 
-cauliflower 
-peas 
-beans 
-asparagus 
-watercress 
-lettuce 
-white cabbage 88-
-winter cabbage52-
-broccoli 
-sprouts 
-spinach 
-kale 
Coffee 
Tea 
147-
1 
6 
5 
27 
29 
46 
57 
88 
120 
-137 
-189 
200 
-400 
415 
724 
37 
712 
Table 1: vitamin K-) content of various food-stuffs according to Lefe-
vere (22). (With permission). 
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Vitamin K-j is easily absorbed in the upper part of the small intestine 
and, due to its apolarity, requires the presence of bile salts (23). 
Vitamin Ki is effectively absorbed by the newborn infant. McNinch et 
al. (24) studied two groups of breast-fed infants, receiving 1 mg vi­
tamin K, one group orally and the other by intramuscular injection. 
During the next 24 hours vitamin K-) plasma levels were measured. In 
babies given the vitamin К orally, the peak median concentration (73 
ng/mL) occurred at four hours. The intramuscular injection gave a peak 
concentration (17B1 ng/mL) which was reached after 12 hours. The au­
thors concluded that since median plasma vitamin K·) levels 24 hours 
after oral administration were 23-32 ng/mL (some 100 and 1000 times 
greater than previous estimated adult and newborn values respective­
ly), this supports the view that vitamin Ki can be given orally at 
birth to healthy term babies. 
Vitamin K2 or menaquinone is produced by the intestinal flora. Bacte-
roides fragilis and some strains of Escherichiae Coll do synthetize 
vitamin K2 (25), but the major bacterial population contributing to 
adult and infant vitamin К supply remains to be identified. To permit 
the absorption of the apolar vitamin «2 bile-salt are required for the 
formation of micelles (23). In the colon where menaquinone is produ­
ced, however, bile-salts are absent. Hollander et al. (26) perfused a 
colonial segment in rats with increasing concentrations of vitamin «2 
(37-300 |ig); they found that using these high concentrations absorp­
tion in the colon took place by a passive diffusion process. 
The stores of vitamin K-| in the human fetus are low, with concentra­
tions in the liver about one-fifth of those in older children and 
adults (12). 
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1.5 CLINICAL MANIFESTATIONS OF VITAMIN К DEFICIENCY 
Haemorrhage due to vitamin К deficiency can be divided into three 
patterns according to Lane and Hathaway (27): early haeroorrhagic di­
sease of the newborn, occurring within 24 hours after birth, classic 
haeroorrhagic disease, occurring between 2 and 5 days of age and late 
haeroorrhagic disease, occurring after one month of age. Early and 
classic haemorrhagic disease of the newborn often present with gastro­
intestinal bleeding, skin bruises, umbilical bleeding or haematuria. 
Late haemorrhagic disease is often accompanied by acute intracranial 
haemorrhage with severe morbidity and mortality. Each localisation of 
the haemorrhage can be present, however, in both early and in classic, 
as well as in late haemorrhagic disease. A patient survey, containing 
our own patients and those from the literature with vitamin K-depen-
dent haemorrhage is presented in Chapter 3. 
1.6 LABORATORY INVESTIGATIONS IN VITAMIN К DEFICIENCY 
In comparison with older children and adults, significant differen­
ces in haemostasis are present in newborns and young infants. Levels 
of most coagulation factors are in the range of 15-70% of normal adult 
values, with the exception of factor V, VIII and XIII which attain the 
adult levels prenatally (28). The levels in premature infants are even 
lower, except the level of factor XIII (28, 29). 
The levels of the vitamin К dependent coagulation factors II, VII, IX 
and X reach adult levels after 3 to 6 month of age (28, Chapter 4). 
The coagulation inhibitor protein С rises from ЗОЙ at birth to adult 
values at about the age of 3 years (Chapter 5). Ankola reported that 
protein С is less functionally active in newborn infants than in 
adults. This lower functional activity did not appear to be due to vi­
tamin К deficiency in their study (30). Information about the protein 
С со-factor protein S is not available. 
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Screening tests reflecting the physiological lower levels of vitamin К 
dependent pro-coagulation factors such as the prothrombin time (PT), 
partial thromboplastin time (PTT) and thrombotest (TT) are also pro­
longed at birth (28). Measurement of vitamin К dependent coagulation 
factors or the prothrombin time, partial thromboplastin time or throm­
botest are not suited for the detection of mild vitamin К deficiency 
(Chapter 4, 5). A significant increase however in the vitamin К depen­
dent coagulation factors or a shortening of the prothrombin time or 
partial thromboplastin time following the administration of vitamin К 
suggests a deficiency state. More specific tests measuring the abnor­
mal des-carboxy-prothrombin are described and evaluated in Chapter 2. 
1.7 TREATMENT OF VITAMIN К DEFICIENCY 
In vitamin К dependent haemorrhage administration of a single pa­
renteral dose of 1 mg vitamin K-| corrects even a severe deficiency. 
In a few hours the prolonged prothrombin-time (PT, Quick), the activa­
ted partial thromboplastine-time (PTT, kaolin-cephalin), and the de­
pressed levels of coagulation factors return to normal. It is more ap­
propriate to administer the vitamin intravenously, as an intramuscular 
injection may be associated with haematoma formation and slower ab­
sorption. For life-threatening haemorrhage vitamin К administration 
must be combined with the infusion of 10 to 20 ml/kg fresh-frozen 
plasma or a concentrate containing the four vitamin K-dependent coagu­
lation factors (Prothrombin complex CLB (Centraal Laboratorium van de 
Bloedtransfusiedienst) : 10 ml corresponds with 200 to 250 ml fresh 
plasma). 
The clinical diagnosis of vitamin К deficiency may be confused with 
disseminated intravascular coagulation (DIC). In DIC, however, fibnn-
fibnnogen degeneration products are present and the platelet-count 
and probably also fibrinogen decrease. We agree with Lane and Hathaway 
(27) that administration of vitamin К should not be delayed m a blee­
ding infant because of difficulty in obtaining adequate samples for 
coagulation studies. Abnormal des-carboxy-prothrombin (PIVKA-II) can 
still be detected in the plasma after the correction of vitamin К de-
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ficiency owing to the half-life of PIVKA-II (Chapter 7).The use of 
vitamin K-) is safe; administration of a dose as high as 10 to 25 mg 
vitamin K-] has not been associated with toxic symptoms or hyperbiliru­
binemia (4). Vitamin К may however have some effect on benzopyrene 
metabolism (31). Israels et al. studied the effect of 5 mg/kg vitamin 
K·) on the mutagenic and carcinogenic effect of benzopyrene adminis­
tered intravenously to mice. This very high dose of 5 mg/kg vitamin K-| 
enhances this effect while vitamin К deficiency protects against the 
mutagenic effect of benzopyrene. The meaning of these results for the 
human situation is not clear. 
1.8 CURRENT CONTROVERSIES 
For those who believe that circumstances are 'ideal' for the child 
during pregnancy and lactation, it is hard to believe that deficien­
cies may occur during this period. In evolution mother and child are 
both important and both mother and child should benefit for the survi­
val of the species. Dugdale in a recent article in the Lancet sugges­
ted that the mother and child dyad is the evolutionary unit (32). The 
dyad hypothesis suggests that the maximum evolutionary gain is obtai­
ned when protein, mineral, vitamin and energy levels during pregnancy 
and lactation are just high enough to prevent prohibitive infant mor­
tality rates, but low enough to spare the mother (32). So the mother 
herself may really need most of the vitamin К she receives. 
Shearer et al. (12) showed that healthy mothers at term had a mean vi­
tamin «1 plasma level of 0.20 ng/mL; healthy adults had a mean plasma 
concentration of 0.26 ng/mL (women 0.22 ng/mL, men 0.30 ng/mL). So 
there seems to be no severe maternal vitamin К deficiency in the peri­
natal period. In small numbers of infants some investigators failed to 
find evidence of vitamin К deficiency at birth. Van Doorm et al. (5) 
failed to find PIVKA-II in 43 consecutive cord-blood samples using a 
rather insensitive immunochemical method. Göbel et al. (7) measured 
factors II and VII in 72-94 hours-old, breast-fed (n=96) and bottle-
fed (n=54) infants receiving their first feed 6 hours after birth. A 
third group (n=19) received their firs^ feed 24 hours after birth. The 
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150 babies with early onset of feeding had a mean concentration of 60% 
of factor II and of 70% of factor VII; 15 infants randomly chosen from 
these 150 received a prophylactic dose of 2 mg vitamin К at birth. No 
significant effect could be detected on factor II and factor VII le­
vels. The infants who received the first feed 24 hours after birth had 
significantly lower factor II and factor VII levels. The authors con­
clusion was that no evidence for vitamin К deficiency could be found 
in normal babies given their first feed soon after birth. 
Mon et el. (8) measured factor II, VII and X coagulation activity in 
31 premature newborns before and 24 hours after parenteral administra­
tion of 0.5 mg/kg vitamin K. For comparison they studied 29 untreated 
preterm babies at the same times. No difference in factor II, VII and 
X coagulation activity was found before and after vitamin К admini­
stration and no difference was found between the two groups. 
Malia et al. (11) found no evidence of vitamin К deficiency in 24 cord 
blood samples by measuring factor II, VII and IX by physiological 
methods and by activation of factor II and factor X by snake venom, 
while factor II was also determined immunologically. Using a more sen­
sitive method, Motohara et al.(33) found PIVKA-II circulating in 21.SO 
of 51 cord blood samples. At the age of 3-5 days 50 to 60% of the in­
fants were PIVKA-II positive when breast-fed without vitamin К prophy­
laxis. The results of our own study are presented in Chapter 7. 
In a recent study Shearer et al could not detect vitamin «i in cord 
blood, indicating that vitamin К deficiency can occur at birth (12) 
The same authors found that vitamin К did not cross the placenta rea­
dily. Our own study on vitamin Ki levels in cord blood and after birth 
is described in Chapter 7. The recent numerous reports in clinical li­
terature as well as the series of patients described in Chapter 3 in­
dicate that the occurrence of vitamin deficiency in breast-fed in­
fants is a serious problem. 
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1.9 PREVENTION OF VITAMIN К DEFICIENCY IN INFANTS 
Vitamin К deficiency can be prevented in different ways. Much expe­
rience has been acquired with the intramuscular injection of 1 mg vi­
tamin «ι, but oral administration to the neonate is also possible 
(24), as well as administration to the mother during pregnancy and 
lactation. 
Intramuscular injection can be associated with haematoma formation and 
the theoretical danger of the confusion of vitamin К with other medi­
cation exists. 
Objections against oral administration to the neonate after birth or 
with the first feed include the possibility of variable absorption and 
unnoticed regurgitation. Dunn (13) added 1 mg vitamin K·) to the first 
feeding of 31,000 newborn infants, with only one case of haemorrhage 
in an infant of a mother taking anticonvulsant drugs. Vitamin K2 also 
seems to be effective after oral administration. Motohara et al. (33) 
measured PIVKA-II in two groups of infants, one (n=51) was given 5 mg 
vitamin K2 orally at birth, whilst the other (n=51) received no vita­
min K2 supplementation. On the third day of life in 61.5% of the un­
treated group PIVKA-II was found (mean level 6.ΘΘ AU/mL) while in only 
18.55« of infants receiving vitamin K2 PIVKA-II (mean level 0.77 AU/mL) 
was found. On day 5 in 52.9% of the untreated group PIVKA-II was pre­
sent (mean level 4.11 AU/mL) while in 11.48 of the treated infants 
PIVKA-II (mean level 0.55 AU/mL) was found. (1 AU = 1 arbitrary unit 
corresponding with 1 ug prothrombin). 
Vitamin К administration to the mother can prevent haemorrhagic disea­
se of infants of epileptic mothers using phenytoin and phenobarbito-
ne. These drugs cause an increased induction of microsomal enzymes in 
the fetal liver (34). These hepatic enzymes may increase the rate of 
oxidative degradation of vitamin К and produce a vitamin К deficien­
cy. Deblay at al. (35) gave 20 mg vitamin K·) daily for two weeks befo­
re delivery to mothers treated with phenobarbitone or phenytoin. On 
this regimen the babies developed no haemorrhages and had normal pro­
thrombin values. Shearer et al.(12) showed that 1 mg vitamin К given 
intravenously to six mothers shortly before delivery raised their 
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plasma vitamin К·) levels to 45-93 ng/mL. Vitamin К was detectable in 
the cord plasma of four of six infants born to these mothers, but in 
very low concentrations, not exceeding 0.14 ng/mL. 
In the same paper (12) Shearer et al. showed that the supply of vita­
min K-| to the breast-fed infant may readily be increased by giving the 
mother supplemental vitamin K·). A single dose of 20 mg vitamin K-j gi­
ven to a lactating mother produced a 70-fold increase of vitamin K-) 
concentration in her breast-milk after 12 hours; after 48 hours the 
level was still twice the mean endogenous level of vitamin К in human 
milk. 
1-1G AIM OF THE STUDY 
The general opinion about vitamin К deficiency at the start of this 
study four years ago was that vitamin К deficiency and vitamin К 
dependent haemorrhage did not occur in healthy full-term neonates. 
Patients with intracranial haemorrhage due to vitamin К deficiency 
admitted to the Nijmegen University Hospital (chapter 3) changed our 
attitude about this subject. 
The purpose of this thesis is to provide information about the 
presence of PIVKA-II and the levels of vitamin K-) in normal neonates 
receiving breast milk or formula and to evaluate the effect of the 
intramuscular injection of one mg of vitamin K-] as a preventive 
measure. 
23 
1-11 REFERENCES 
1. Waddel W.W., Guerry D., Bray W.E., Kelly O.R.: Possible effects of 
vitamin К on prothrombin and clotting time in newly born infants. 
Proc. Soc. Exp. Biol. Med. 1939; 40: 432-434. 
2. Dam H., Tage-Hansen E., Plum P.: Vitamin К lack in normal and sick 
infants. Lancet 1939; iit 1157-1161. 
3. Ansbacher S., Fernholz E.: Simple compounds with vitamin К activi­
ty. J. Am. Chem. Soc. 1939; 61: 1924-1930. 
4. Committee on Nutrition, American Academy of Pediatrics. Vitamin К 
compounds and the water soluble analoques. Pediatrics 1961; 2B: 
501-507. 
5. van Doorm J.M., Muller A.D., Hemker H.C.: Heparin-like inhibitor, 
not vitamin-K deficiency, in the newborn. Lancet 1977; i: 852-853. 
6. Edson J.R.: Vitamin-K deficiency in the newborn. Lancet 1977; ii: 
187. 
7. Göbel U., Sonnenschein-Kosenow S., Petrich С , von Voss H.: Vita­
min-K deficiency of the newborn. Lancet (1977); ii: 187-188. 
8. Mori P.G., Bisogni С , Odino S., Tonini G.P., Boeri E., Serra G., 
Romano С : Vitamin-K deficiency in the newborn. Lancet (1977); ii: 
188. 
9. Aballi A.J.: Vitamin-K deficiency of the newborn. Lancet 1977; ii: 
559. 
10. Anonymous. Vitamin К and the newborn. Lancet 1977; i: 755-757. 
11. Malia R.G., Preston F.E., Mitchel V.E.: Evidence against vitamin К 
deficiency in normal neonates. Thromb. Haemostas 1980; 44: 159-160 
12. Shearer M.J., Rahim S., Barkhan P., Stimmler L.: Plasma vitamin K-| 
in mothers and their newborn babies. Lancet 1982; ii: 460-463. 
13. Dunn P.M.: Vitamin К for all newborn babies. Lancet 1982; ii: 770. 
14. Aballi A.J.: Vitamin К deficiency in breast-fed infants. J. Pedi-
at. 1984; 106: 1059. 
15. Mezick J.Α., Settlemire C.T., Brierly G.P., Barefield K.P., Jensen 
W.N., Cornwell D.G.: Erythrocyte membrane interactions with 
menadione and the mechanism of menadione-induced hemolysis. 
Biochim. Biophys. Acta 1970; 219: 361-371. 
24 
16. Friedman P.A.: Vitamin-K dependent proteins. N. Eng. J. Med. 19B4; 
310: 1458-1460. 
17. Suttie J.W.: Mechanism of action of vitamin K: synthesis of gamma 
carboxyglutamic acid. 1980; CRC 24: 191-223. 
18. Shearer M.J., Allan V., Haroon Y., Barkhan P.: Nutritional aspects 
of vitamin К in the human. In: Vitamin К metabolism and vitamin 
K-dependent proteins. J.W. Suttie, Univ. Park Press, Baltimore 
1980; 317-327. 
19. Hamulyak K.: Aspects of the haemostatic mechanism in newborns. 
Thesis, State University of Maastricht, The Netherlands, 1985; p. 
77-87. 
20. Haroon Y., Shearer M.J., Rahim S., Gunn W.G., McEnery G., Barkhan 
P.: The content of phylloquinone (vitamin K-) ) in human milk, cows' 
milk and infant formula foods determined by high-performance 
liquid chromatography. J. Nutr. 1982; 1i2: 1105-1117. 
21. von Kries R., Göbel U., Shearer M.J., McCarthy P.T.: Vitamin К 
deficiency in breast-fed infants. J. Pediat. 1985; 107: 650-651. 
22. Lefevere M.F.L.: Bioanalytische studie van vitamin K. Thesis, 
State University of Gent, Belgium, 1982; p.30. 
23. Shearer M.J., Barkhan P., Webster G.R.: Absorption and excretion 
of an oral dose of tritiated vitamin K-) in man. Br. J. Haematol. 
1970; 18: 297-308. 
24. McNinch A.W., Upton C , Samuels M., Shearer M.J., McCarthy P., 
Tripp J.H.E., Orme R.L.: Plasma concentrations after oral or 
intramuscular vitamin K-) in neonates. Arch. Dis. Child. 1985; 60: 
814-818. 
25. Bentley R., Meganathan R.: Biosynthesis of vitamin «2 (menaquino-
ne) in bacteria. Microbiol. Rev. 1982; 46: 241-280. 
26. Hollander D., Rim E., Ruble P.E.: Vitamin K2 colonic and ileal in 
vivo adsorption: bile, fatty acids and pH effects on transport. 
Am. J. Physiol. 1977; 233: 124-129. 
27. Lane P.A., Hathaway WmE.: Vitamin К in infancy. J. Pediat. 1985; 
106: 351-358. 
28. Bleyer W.A., Hakami N., Shepard Т.Н.: The development of hemosta­
sia in the human fetus and newborn infant. J. Pediat. 1971; 79: 
838-853. 
25 
29. Beverley D.W., Inwood M.J., Chance G.W., Schaus M., O'Keefe В.: 
'Normal' haemostasis parameters: a study in a well-defined inborn 
population of preterm infants. Early Hum. Development 1984; 9: 
249-257. 
30. Ankola P., Nardi M.A., Karpatkin M.: Protein С in newborn infants 
has lower functional activity than in adults. Ped. Res. 1986; 20: 
387a. 
31. Israels L.G., Ollmann D.J., Israels E.D.: Vitamin K-) as a modula­
tor of benzo(a)pyrene metabolism as measured by in vitro metaboli­
te formation and in vivo DNA-adduct formation. Int. J. Biochem. 
1985; 17: 1263-1266. 
32. Dugdale A.E.: Evolution and infant feeding. Lancet 1986; i: 670-
673. 
33. Motohara K., Endo F., Matsuda I.: Effect of vitamin К administra­
tion on acarboxy prothrombin (PIVKA-II) levels in newborns. Lancet 
1985; ii: 242-244. 
34. Keith D.A., Gallop P.M.: Phenytoin, hemorrhage, skeletal defects 
and vitamin К in the newborn. Med. Hypotheses 1979; 5: 1347-1350. 
35. Deblay M.F., Vert P., Andre M., Marchai F.: Transplacental vitamin 
К prevents haemorrhagic disease of infants of epileptic mothers. 
Lancet 1982; i: 1247. 
26 
CHAPTER 2 
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2.1. ABSTRACT 
PIVKA-II is abnormal des-carboxylated prothrombin present in 
vitamin К deficiency-state or in patients using warfarin. By a 
sensitive method to detect PIVKA-II, biochemical vitamin К defi­
ciency can be established before clinical symptômes occur. Many 
methods are used to detect PIVKA-II. An overview about these 
methods is given and four selected methods are compared to each 
other. 
1. ECar minus XaPC method, measuring total factor II including 
PIVKA-II by using Echis Carinatus snake venom as an activator of 
prothrombin in comparison with functional factor II by using its 
natural activators namely factor V, factor Xa, phospholipid and 
calcium. This method is fast and suitable for clinical use but 
rather insensitive. 
2. BaSO^ method, measuring PIVKA-II by using snake venom as an 
activator of factor II after adsorption of functional factor II 
to barium sulfate. The optimal conditions for the BaSO^ adsorp-
tion were established. It appeared that a part of the PIVKA-II is 
also adsorbed. With some adjustments this method is suitable for 
clinical use. It is a fast method and rather sensitive. 
3. Electrophoresis-immunofixation method, developed in our labo-
ratory, separating factor II and PIVKA-II electrophoretically in 
the presence of calcium, followed by immunofixation is a time 
consuming and rather sensitive method. This kind of method can 
give false-positive results if coagulation takes place in the 
test tube. 
4. Enzyme immunoassay, using monoclonal antibodies specific to 
PIVKA-II is a fast and by far the most sensitive method. 
For the measurement of PIVKA-II, before a clinical bleeding ten-
dency is present, the EIA is the most sensitive and reliable me-
thod. 
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2.2. INTRODUCTION 
In a bleeding neonate or young infant, haemorrhagic disease 
caused by vitamin К deficiency should be differentiated from 
bleeding secondary to other causes. In the past, assesment of 
vitamin К status in infancy has relied on assays of the vitamin 
K-dependent coagulation factors or the prothrombin time (PT), the 
partial thromboplastin time (PTT), the thrombotest (TT) (Nye-
gaard), or the normotest (NT) (Nyegaard) and of comparing the re­
sults of these tests with those in normal infants. A decrease in 
the levels of vitamin K-dependent coagulation factors, or a pro­
longed PT, PTT, TT or NT corrected by the administration of vita­
min K, suggests a vitamin К deficiency. 
Vitamin К is required for the posttranslational carboxylation 
of glutamic acid residues on the amino terminal part of the vita­
min K-dependent proteins. The gamma-carboxyglutamic acid residues 
formed provide these proteins with unique calcium and phospho­
lipid binding properties. The coagulation factors II, VII, IX and 
X and the coagulation inhibitors protein С and protein S are the 
best known vitamin K-dependent proteins, but there are other 
vitamin К dependent proteins, like osteocalcin, whose specific 
function is less well understood (1, 2). 
In vitamin К deficiency state des-carboxylated proteins are 
formed which are functionally defective because they cannot bind 
calcium and phospholipid. These abnormal coagulation factors are 
called PIVKAs (Protein Induced by Vitamin К Absence). PIVKA-II is 
des-carboxylated prothrombin. 
Tests measuring these abnormal des-carboxylated proteins 
(PIVKA assay) circulating in vitamin К deficient patients are 
more specific than the functional assays. By measuring PIVKA, 
detection of biochemical vitamin К deficiency is possible before 
conventional coagulation tests are disturbed (3) or manifest hae­
morrhage occurs. In normal controls PIVKAs are absent, but in li­
ver disease and liver malignancy PIVKAs can be present even in 
the absence of vitamin К deficiency (4, 5, 6). 
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Several methods to detect PIVKA-II make use of the difference 
between PIVKA-II and normal carboxylated prothrombin. PIVKA-II is 
antigenically almost equal to active prothrombin, but functional­
ly defective. One method compares the level of prothrombin measu­
red functionally with that measured immunochemically, represen­
ting total prothrombin (7). A low coagulant/ antigen ratio indi­
cates vitamin К deficiency. Snake venom used as an activator for 
the total amount of prothrombin including PIVKA-II permits the 
use of the ratio coagulant/total factor as an indication of vita­
min К deficiency. Again a low ratio coagulant/total factor II in­
dicates vitamin К deficiency (8). In a second type of assays car­
boxylated prothrombin is adsorbed to barium carbonate, barium 
sulphate or aluminium hydroxide gel and the remaining des-carbo-
xylated PIVKA-II is assayed immunochemically or by using snake 
venom or with an assay based on agglutination of antihuman pro­
thrombin rabbit IgG coated latex particles (9, 10, 11, 12). In a 
third technique PIVKA-II can be separated from fully carboxylated 
prothrombin by electrophoresis, as PIVKA-II is migrating faster 
than prothrombin in a calcium containing medium (13, 14). The two 
proteins can also be separated by liquid chromatography with the 
aid of an anion-exchange column (15). Finally direct measurements 
are performed with monoclonal or polyclonal antibodies specific 
to PIVKA-II in a radio immunoassay (RIA) or enzyme immunoassay 
(EIA)(16, 17). 
According to Soute et al. (15) prothrombin contains 10 gamma-
carboxy residues which are absent in PIVKA-II. Hence prothrombin 
has 10 more negative groups than PIVKA-II. The question wether 
PIVKA-II is not-carboxylated or under-carboxylated is not defini­
tely solved. Malhotra supports the view that in vitamin К defici­
ency or vitamin К antagonism only a part of the ten glutamic acid 
residues present at the aminoterminal end are not carboxylated 
into gamma carboxy glutamic acid (18, 19, 20).The finding of two 
spikes in high performance liquid chromatography (15) or two 
bands in electrophoresis (13, 14) in plasma of patients using 
warfarin or with a vitamin К deficiency supports the theory that 
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Р1 КА-П none of the ten glutamic acid residues at its NH2-termi-
nal end are carboxylated. 
Four different types of assays were evaluated and compared to 
each other. 
2.3. MATERIALS AND METHODS 
Human blood was drawn by venipuncture and collected in a 1:10 
volume sodium citrate solution (34,2 mmol/L) in plastic tubes. To 
the blood samples 200 kilo int units Trasylol (Bayer) were added 
to one mL of blood in order to prevent proteolysis. The platelet-
free plasma obtained after centrifugation at 20,000 g (30 min, 
40C) was stored at -70°C. 
Pooled normal plasma was made up from platelet-free plasma taken 
from 40 healthy adults. 
Thrombotest measurement was performed according to the instruc­
tions of the manufacturer (Nyegaard, Norway). Results are expres­
sed in percentage terms of pooled normal plasma. 
I. Measurement of functional and of total prothrombin: 
From the methods comparing functional prothrombin and total pro­
thrombin including PIVKA-II we choose the method described by 
Bertina et al. (θ), an easily applicable and reliable method. 
- the X
a
PC-method measures only functional factor II; the deter­
mination was performed as previous described (Θ). Briefly: func­
tional prothrombin is converted into thrombin by factor V already 
present in the plasma at a normal adult level and by the action 
of added factor X
a
, phospholipid (Cephaline) and Calcium (X
a
PC). 
The resulting thrombin activity is measured using chromogenic 
substrate 52238 (Kabi Vitrum). The method was adapted to the use 
of the Cobas Bio centrifugal analyzer. Plasma standard and pa­
tient plasma were diluted in the ratio of one part plasma to 
three parts saline solution and 5 uL of this diluted plasma was 
used in the test. Incubation time was 60 s instead of 90 s. Re­
sults are expressed as a percentage of pooled normal plasma. 
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- the ECar-method measures both factor II and des-carboxylated 
factor II. The measurement was performed as previously described 
(Θ). Briefly: total prothrombin including PIVKA-II is converted 
into thrombin by means of the venom of Echis Carinatus (ECar). 
The resulting thrombin activity is measured using chromogenic 
substrate 52238 (Kabi Vitrum). The method was adapted to the use 
of the Cobas Bio centrifugal analyzer. The same plasma dilution 
was used as in the X
a
PC-method. Results are expressed as a per­
centage of pooled normal plasma. 
Bertina et al. (8) calculated the ratio X
a
PC/ECar. According to 
them a ratio < 0.86 conclusively established the presence of 
PIVKA-II. We calculated PIVKA-II concentrations by substracting 
the results of the X
a
PC method from the results of the ECar me­
thod (ECar minus X
a
PC method) to allow a better comparison with 
the other techniques. 
II. The adsorption method. 
From the adsorption methods, adsorption to BaS04 (white standard 
Merck, art n 0 1748) was chosen as described by Shah et al. (12). 
Blood was obtained from warfarin treated persons with low and 
high thrombotest values. All adsorption experiments were perfor­
med in a slowly rotating mixing device. The X
a
PC and ECar method 
were carried out as described. The absorption experiments were 
performed under various experimental conditions. Firstly BaSO^ 
was added in different quantities; 40-60-80 g/L was added to 
plasma . Adsorption was performed at room temperature for one 
hour.Secondly adsorption upto 80 g/L of BaSO^ was performed at 
0oC and at room temperature during one hour. Adsorption upto 80 
g/L of BaSO^ was also performed over different periods of time 
(30-60-90-120-180 minutes) at room temperature. Finely adsorption 
to 80 g/L of BaSO^ was repeated five times consecutively in the 
same samples. After each adsorption,X
a
PC and ECar measurement 
were performed in the supernatant after centrifugation.BaSO^ pre­
viously washed with 34,2 mmol/L sodium citrate solution was also 
used as has been described in the literature (12). Adsorption was 
performed during one hour at room temperature. The results with 
citrate washed and unwashed BaSO^ were compared. 
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III. Electrophoretical method. 
An electrophoretical separation plus immunofixation was developed 
in our laboratory. 
After electrophoresis of the plasma on a cellogel membrane (Che-
motron, Milan) for 40 min in Veronalbuffer (pH Θ.6) containing 
Calcium lactate (2.0 mmol/L), the electrophoresis-strip was cove­
red for four hours with a cellulose acetate strip moistened with 
0.2 mL/cm^ of rabbit anti-prothrombin antiserum (anti-prothrom-
bin, Behring Werke). The electrophoresis strip was washed in sa­
line solution overnight. To intensify the primary immunо precipi­
tate a second immunofixation was performed with goat antirabbit-
immunoglobulin (Dako) for 4 hours. After thoroughly washing for 2 
days in saline solution the immunoprecipitates were stained with 
amido black 10B (Merck) and subsequently destained with a mixture 
of methanol,acetic acid and water (5:1:4). The strip is cleared 
with methanol-acetic acid (85:15) and dried on a glass plate at 
100oC. The presence of two bands is indicative for PIVKA-II. 
IV. The EIA method using a monoclonal antibody specific to abnor­
mal prothrombin (PIVKA-II) was performed as previously described 
(17) in cooperation with Kumamoto University Medical School in 
Japan. Briefly: diluted plasma samples were put into polystyrene 
wells previously coated with the monoclonal anti-PIVKA-II anti­
serum. After washing, peroxidase labelled anti-prothrombin anti­
serum was added to the wells. After washing the bound peroxidase 
activity was measured. 
All four methods were performed in plasma from healthy volun­
teers, in the normal plasma pool and in plasma from patients re­
ceiving oral anticoagulants. The detection limit of the ECar mi­
nus X
a
PC method and the ECar measurement after BaSO^ absorption 
was established. Plasma of a warfarin treated patient with a low 
thrombotest value was diluted serially with the plasma of a heal­
thy volunteer to compare the methods used. PIVKA-II content was 
established from the difference between ECar and X
a
PC measurement 
in the same plasma sample, from the ECar value after two consecu­
tive adsorptions with 80 g BaSO^ per L of plasma and from the di­
rect measurement of PIVKA-II using EIA. PIVKA-II is expressed in 
percentage terms from the normal plasma pool and as arbitrary 
units (AU)/mL in the EIA; one AD corresponding to on ug of pro­
thrombin (17). As normal plasma contains 100-200 mg/L of pro­
thrombin (21), 1°o in the first and second method is approximately 
1-2 AU/mL in the EIA. 
2.4. RESULTS 
2.4.1. The ECar minus X
a
PC method. 
In the plasma of 20 healthy individuals (11 adults and 9 infants) 
the concentration of prothrombin was assayed both by the X
a
PC and 
ECar technique. The results are presented in the first part of 
table 2-1. The difference between ECar and X
a
PC values was calcu­
lated. A mean value of 1.3 * 1.6S was found. The detection limit 
of PIVKA-II was: 4. Й. 
2.4.2. BaSO^ experiments. 
No different results were obtained wether the adsorption was per­
formed at room temperature or at 40C (data not shown). So all ot­
her experiments were performed at room temperature. The results 
of BaSO^ adsorption with and without citrate washing of the 
BaSO^, revealed that citrate washing made the adsorption less 
effective (data not shown). The results of the X
a
PC and ECar 
measurement in plasma with a low and a high thrombotest value 
after adsorption with different quantities of BaS04 during one 
hour reveal that not all functional factor II, as measured by the 
X
a
PC method, is adsorbed after one hour even with the highest 
amount of ВаЗОд (ВО g/L) (table 2-2). Adsorption with 80 g/L of 
BaSO/j during different periods of time show that from 60' on no 
time dependency could be stated. So one hour was chosen as a 
standard time (table 2-3). The results of X
a
PC and ECar measure­
ment in plasma samples with a low and a high thrombotest value 
after consecutive adsorptions with 80 g/L of BaSO^ revealed that 
two adsorptions were needed to remove all functional factor II, 
as measured by the X
a
PC method (table 2-4). From ECar measure­
ments it appeared that after consecutive adsorptions small 
amounts of PIVKA-II are also removed. Therefore extrapolation of 
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ECar after BaSO^ 
Person Х
Я
РС 
1 
2 
3 
4 
5 
6 
7 
θ 
9 
10 
11 
12 
13 
14 
15 
16 
17 
IB 
19 
20 
mean 
S.D. 
(90S ι 
9 6 . 9 
111.0 
110.0 
106.4 
6 8 . 9 
107.2 
104.1 
7 6 . 8 
101.0 
8 4 . 5 
108.9 
5 7 . 4 
7 0 . 9 
4 7 . 9 
4 2 . 9 
5 4 . 2 
6 3 . 5 
53.9 
6 2 . 5 
3 9 . 0 
ECar 
9 6 . 7 
110.7 
109.0 
107.6 
7 1 . 6 
108.0 
106.7 
7B.7 
103.3 
8 6 . 2 
107.9 
5 6 . 2 
7 3 . 6 
5 0 . 2 
4 3 . 8 
5 4 . 4 
6 3 . 3 
5 7 . 7 
6 6 . 1 
4 2 . 0 
: o n f i d e n c e l i m i t s 
ЕСаг-Х
я
РС 
- 0 . 2 
- 0 . 2 
- 1 . 0 
+ 1 . 2 
+ 2 . 7 
+ 0 . 8 
+ 2 . 6 
+ 1 . 9 
+2.3 
+ 1 . 7 
- 1 . 0 
- 1 . 2 
+ 2 . 7 
+ 2 . 3 
+ 0 . 9 
+ 0 . 2 
- 0 . 2 
+ 3 . 8 
+ 3 . 6 
+ 3 . 0 
1.3 
1.6 
3 . 3 - 4 . 8 
a b s o r p t i o n 
0.35 
0.29 
0.21 
0.19 
0.22 
0.29 
0.32 
0.19 
0.22 
0.22 
0.07 
0.06 
0.21 
0.20 
0.12 
0.28 
0.36 
0.06 
0.18 
0.26 
0.22 
0.09 
0 . 3 3 - 0 . 4 1 
EIA 
< 0 . 1 3 
<r0.13 
< 0 . 1 3 
¿ 0 . 1 3 
< 0 . 1 3 
< 0 . 1 3 
<r0.13 
^ 0 . 1 3 
<r0.13 
< 0 . 1 3 
< 0 . 1 3 
¿ 0 . 1 3 
<:o . i3 
< 0 . 1 3 
< 0 . 1 3 
< 0 . 1 3 
< 0 . 1 3 
< 0 . 1 3 
¿ 0 . 1 3 
¿ 0 . 1 3 
TT 
56 
72 
70 
80 
>100 
82 
¿100 
?100 
88 
>100 
Я 0 0 
* 1 0 0 
>100 
>100 
>100 
>100 
¿100 
>100 
>100 
>100 
Table 2-1: Results of the ECar minus XaPC method, the ВаЗОд 
adsorption method and the EIA in 20 healthy individuals (1-11 
adults, 12-20 infants of three month of age). Thrombotest values 
are also presented. Results are expressed in percentage terms of 
the normal plasma pool or as AU/ml in the EIA. 
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the ECar values to zero time provide the most accurate PIVKA-II 
values. For practical reasons the ECar value after two consecuti-
ve adsorptions with 80 g/L of BaS04 is considered to represent 
PIVKA-II in the sample. The results of the FCar measurement after 
BaSO^ absorption in plasma of 20 healthy individuals are shown in 
the second part of table 2-1. A mean value of 0.22 ± 0.09;£ was 
found with a detection limit of 0.41л. 
Before adsorption After adsorption with ВаЗОд 
40 60 ВО g/L 
XaPC ECar Х
Я
РС ECar X
a
PC ECar X
a
PC ECar 
TT 100X 111.3 108.В 39.1 37.0 8.7 10.0 1.7 2.4 
TT 7 % 20.7 57.6 2.0 33.2 0.4 29.9 0.3 28.1 
Table 2-2. Results of X
a
PC and ECar measurement in plasma with a 
high and a low thrombotest value after adsorption with different 
quantaties of BaS04 over one hour at room temperature in a slow­
ly rotating mixing device. Results are expressed in percentage 
terms of the normal plasma pool. 
Thrombotest 60% Г[5 
time 
0 
30' 
60' 
90' 
120' 
180' 2.6 4.6 0.3 27.1 
Table 2-3. Results of X
a
PC and ECar measurement in plasma with a 
high and a low thrombotest value after adsorption with 80 g/L 
BaSO^ during different periods of time at room temperature in a 
slowly rotating mixing device. Results are expressed in percen­
tage terms of the normal plasma pool. 
XaPC 
95.1 
2.3 
1.6 
1.2 
1.0 
.6 
ECar 
96.6 
4.3 
3.5 
3.0 
2.8 
.6 
XaPC 
35.1 
0.5 
0.3 
1.7 
0.3 
ECar 
71.6 
26.3 
26.0 
31.9 
26.8 
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80.3 
1.1 
0.1 
0 
0 
0 
90.6 
7.0 
4 .0 
3.2 
2.7 
2 .3 
80.3 
0.2 
0.3 
0 
0 
0 
90.6 
31.4 
26.0 
22.5 
19.3 
16.4 
number o f TT 45;. TT 5?¿ 
a d s o r p t i o n s Х
Я
РС ЕСаг ХдРС ЕСаг 
0 
1 
2 
3 
4 
5 
Table 2-4: Results of ХаРС and ЕСаг measurement in plasma samples 
with a high and a low thrombotest value after one to five conse­
cutive adsorptions with 80 g/L of ВаЗОд over one hour at room 
temperature in a slowly rotating mixing device. Results are ex­
pressed in percentage terms of the normal plasma pool. 
2.4.3. Electrophoretical separation plus immunofixât ion. 
A series of mixtures of normal plasma and of warfarin treated 
patient plasma was used to establish the detection limit of the 
electrophoresis-immunofixation method. This method is only semi-
quantitively, because the amount of immunoprecipitate formed not 
only depends on the amount of factor-II or PIVKA-II present, but 
also on the quality of the antisera used. The detection limit for 
PIVKA-II was estimated to be about 5 AU/mL PIVKA-II (fig 2-1; the 
numbers are corresponding to the numbers in table 2-5). 
2.4.4. The PIVKA-II enzyme immunoassay. 
The detectionlimit of the EIA was previously established to be 
0.13 AU/mL (one arbitrary unit (AU) corresponding to one ug of 
prothrombin). As shown in the third part of table 2-1 no PIVKA-II 
could be detected by this method in healthy individuals. 
We also tried to evaluate the BaS04 adsorption method by measu-
ring PIVKA-II with the EIA. However, dilution of plasma samples 
with saline solution in which BaSO^ was suspended appeared to in-
fluence strongly non specific binding in the immunoassay. 
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Figure 2-1: Immunofixation after elctrophoresis of mixtures of 
normal plasma (TT 100%) and patient plasma (TT 3%). The numbers 
are corresponding to the numbers in table 1. 
№ 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
TT 3% 
1000 
750 
500 
250 
100 
50 
10 
0 
TT 100% 
0 
250 
500 
750 
900 
950 
990 
1000 
Х
Я
РС 
22.8 
46.0 
66.5 
88.3 
100.3 
103.6 
108.5 
108.9 
ЕСаг 
65.3 
76.3 
86.1 
96.6 
103.2 
104.9 
106.6 
107.9 
ЕСаг-Х
я
РС 
42.5 
30.3 
19.6 
8.3 
2.9 
1.3 
-1.9 
-1.0 
ECAR 
after BaSOi 
32.1 
23.4 
16.5 
8.0 
3.1 
1.5 
0.4 
0.1 
EIA 
109.00 
70.80 
50.40 
24.40 
8.40 
5.10 
1.10 
0.13 
Table 2-5: Results of X
a
PC and ECar method, the BaS04-adsorption 
method (two consecutive adsorptions with 80 g/L BaSO^) and the 
EIA in mixtures of normal plasma (ТТЮОл) and patient plasma (TT 
3%). Results are expressed in percentage terms of the normal 
plasma pool or as AU/ml in the EIA. 
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We compared the ECar minus X
a
PC method to the EIA in plasma of 20 
patients treated with warfarin for thrombosis prevention while no 
other medication was taken. P1VKA-1I values expressed as the 
difference between ECar and X
a
PC measurements show a good 
correlation with the EIA results in a range up to 30 AU/mL 
(R=0.95). Above this value no correlation between both methods 
could be demonstrated; this can be due to the inhibitory effect 
of PIVKAs on coagulation. High levels of PIVKA present probably 
interfere strongly with the X
a
PC method (22). 
2.5. DISCUSSION 
There is a mounting interest in the vitamin К status of the 
newborn and particular in breast-fed infants. Intracranial hae­
morrhage occurs more frequently in breast-fed than in bottle-fed 
infants (23). For the detection of vitamin К deficiency the mea­
surement of des-carboxylated prothrombin (PIVKA-II) is a excel­
lent method, while the conventional coagulation tests have a 
diagnostic limitation (3). The detection of small quantities of 
circulating PIVKA-II could be the first signal for a bleeding 
tendency in a vitamin К deficient infant. 
Several methods for the measurement of PIVKA-II are currently 
in use. The aim of this study was to compare the different me­
thods mostly applied to detect PIVKA-II and to establish the de­
tection limit of these methods. 
1. In the ECar minus X
a
PC method the difference is established 
between total factor II including des-carboxy prothrombin (ECar) 
and functional factor II (X
a
PC). The method is reliable and fast 
with a detection limit of 4.5% PIVKA-II present corresponding to 
about 4.5-9 AU/mL. About 50 JJL of plasma is needed. 
2. The detection of PIVKA-II by use of Echis Carinatus venom af­
ter adsorption of factor II to BaSO^ is a fast and reliable me­
thod. Contrary to the report of Shah et al. (12) who used 40 g/L 
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of BaS04 we found that only after two consecutive adsorptions 
with BO g/L of unwashed BaS04 all functional prothrombin was re­
moved from the plasma. However some PIVKA-II is also adsorbed 
from the plasma. This method has a detection limit of ϋΛ°ί PIVKA-
II present corresponding to about 0.4-0.8 AU/mL. About 500 yuL of 
plasma is needed. 
3. The inmunofixâtion after electrophoretical separation of fac-
tor II from PIVKA-II in the presence of calcium is a time-con-
suming method (about 5 days). Falsely positive results can be ob-
tained with this method if some coagulation occurs in the test-
tube. During the conversion into thrombin, prothrombin is firstly 
cleaved into prothrombin-fragment 1 and prethrombin 1 (24). Pro-
thrombin- fragment 1 can mimic PIVKA-II in electrophoresis as it 
shows the same electrophoretical mobility as PIVKA-II. The detec-
tion limit of this method is about 5 AU/mL. About 100 pL of plas-
ma is needed 
4. The EIA as developed by Motohara et al. (15) is a fast and ve-
ry sensitive method. The detection limit of the EIA was previous-
ly established to be 0.13 AU/mL corresponding to 0.13 mg/L pro-
thrombin (15). For this method 100 μί. of plasma is needed. 
The comparison of this four methods to detect a subclinical vita­
min К deficiency by measuring PIVKA-II reveals that the EIA is by 
far the most sensitive method, using only small amounts of plas­
ma. In studies on the incidence of vitamin К deficiency in 
(breast-fed) infants and the effect of different ways of vitamin 
К prophylaxis on the prevention of vitamin К deficiency this me­
thod provides us with an excellent instrument to perform this 
kind of studies. 
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CHAPTER 3 
INFANTS WITH VITAMIN К DEPENDENT HAEMORRHAGE. 
This chapter summarizes case reports published by us in the "Neder­
lands Tijdschrift voor Geneeskunde" (1) and data from the literature 
on young infants with vitamin K-dependent haemorrhage. The patients 
described were admitted to the University Hospital in Nijmegen over a 
three year period, shortly before and during the preparation of this 
thesis. 
3.1 OWN PATIENTS 
Patient A, a boy, was born after an uneventful pregnancy of 39 
weeks. Birthweight was 3290 g. No vitamin К prophylaxis was given in 
the hospital where the delivery took place. The boy was exclusively 
breast-Fed. He gained weight and in the First Few weeks of life he was 
in good health. Mother and child did not take any medication. At the 
age of four weeks the stools became blood-stained and the child became 
less active. A few days later he was admitted to our hospital because 
of pallor and drowsiness. 
Physical examination: length 58 cm, weight 4010 g, head circumference 
39.7 cm (P90). He was irritable and showed marked neck retraction with 
hyperreflexia. Finally he went into shock. 
Laboratory findings: Hb 4.2 mmol/L, aspartate-aminotransferase (ASAT) 
19U/L, alanine-aminotransferase (ALAT) 1Θ U/L, LDH 332 U/L, gamma-GT 
26 U/L, bilirubin 76 umol/L, total protein 61 g/L, albumin 41 g/L. 
Thrombotest 3?ó, partial thromboplastin time (PTT) 600 s (reference 
42.8 s), prothrombin time (PT) 120 s (reference 14.7 s). The cerebro-
spinal fluid contained blood but no micro-organisms. 
Computed tomography (CT) scan showed blood between the tentorium bla-
des and the diagnosis was intracranial bleeding due to vitamin К defi­
ciency . 
The child received a blood transfusion and was treated by administra­
tion of four-coagulation-factors-concentrate (PPSB) and vitamin Κι (3 
mg) intravenously. Thereafter coagulation returned to normal and re-
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mained normal. The patient recovered completely. 
Patient B, a boy, was delivered at home after an uneventful preg­
nancy of 37 weeks. Birthweight was 3550 g. No vitamin К was administe­
red. The child was exclusively breast-fed. In the first few weeks of 
life no problems occurred. At the age of four weeks bruising became 
evident on the back, tibia region and head. He vomitted increasingly. 
A week later he became jaundiced and developed a bulging fontanel. The 
next day convulsions occurred and the child was admitted to our hospi­
tal. 
Physical examination: length 53 cm, weight 4000 g, head circumference 
36.7 cm (P50). The child was hypotonic and showed nghtsided facial 
palsy. 
Laboratory findings: Hb 6.3 mmol/L, Na 119 mmol/L, bilirubin 93 umol/ 
L, alkanine phosphatase 323 U/L, ASAT 84 U/L, ALAT 100 U/L, LDH 731 
U/L, gamma-GT 42 U/L. Thrombotest 3%, PTT and PT were extremely pro­
longed. Factor V 100%, factor II 2.5Й, factor VII 1» and factor IX 
1й. Protein Induced by Vitamin К Deficiency (PIVKA) was present (fac­
tor II coagulation activity 2.55o, factor II determined with snake ve­
nom 25%). A lumbar puncture revealed blood-stained cerebro-spinal 
fluid. 
Echo-encephalography indicated the presence of blood in the arachnoi­
dal space. The diagnosis was vitamin K-dependent intracranial blee­
ding. Therapy consisted of fresh plasma, four-coagulation-factors-con-
centrate and vitamin K-j (1 mg) intravenously. Posthaemorrhage hydroce­
phalus developed and ventnculo-pentoneal shunting was necessary. The 
liverfunction disturbances remained; histological examination revealed 
the presence of neonatal giant-eel hepatitis. Subsequently a spastic 
diplegia became obvious. 
Patient C, a boy, was born after an uneventful pregnancy of 41 
weeks. He was delivered by vacuum-extraction. No vitamin К was admini­
stered. Birthweight was 4380 g, length 53 cm, head circumference 35 
cm. (P50). He was exclusively breast-fed. He had slight neonatal jaun­
dice. At the age of 4'/2 weeks he had a nose bleed once. A few days 
later he was admitted to the hospital because of poor sucking, drowsi­
ness and seizures. 
Physical examination: length 57.5 cm, weight 4850 g, head circumferen-
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Patient age bleeding site liver function vitamin К deficiency 
disorder 
diagnosis/evolution 
D,male θ wks bleeding in tumor yes TT S%, PIVKA-II present choriocarcinoma 
died 
E,female 3 wks intestinal, intracra­
nial 
yes TT 36%—•100Ä after 1 mg vita- biliary atresia 
min «i i.m. cerebral palsy 
F,male 4 wks intestinal 
G,female 2 days haematuria 
H,female 4 days no apparent 
bleeding 
yes 
no 
TT ЗЙ—100« after 5 mg 
vitamin Κι orally 
TT Зй—41Й a f t e r twice 
1 mg vi tamin K<| i . v . 
PIVKA-II present 
biliary atresia 
died 
complete recovery 
TT 3%—-76% after 5 mg vitamin severe coarctatio aortae 
K-j orally, PIVKA-II present died 
I,female 2 days intestinal 
intracranial 
J,female 4 days intracranial 
no TT 27% after 1 mg vitamin К died from intra cerebral 
intravenous. PIVKA-II present bleeding 
no PIVKA-II present subdural haematoma 
removed after trepanation 
Table 3-1 ; Patients with vitamin К dependent haemorrhage. 
TT = Thrombotest 
PIVKA-II = Protein Induced by Vitamin К absence 
ce 39.θ cm (P90). He was pale and drowsy. He had a tensely bulging 
fontanel. He had bruises on his legs. There was no abdominal tender­
ness, on palpation the liver was enlarged, the spleen was not palpa­
ble. 
Laboratory findings: Hb 5.θ nrniol/L, thrombocytes 852x109/L, A5AT 36 
U/L, ALAT 35 U/L, gamma-GT 113 U/L, bilirubin 108 jjmol/L. Microscopic 
haematuria was present. Fibrinogen 2.9 g/L (N=1.5-4.5 g/L), PTT 221 s 
(reference 30-45 s), PT 148 s (reference 11-13 s). PIVKA-II was pre­
sent (factor II coagulation activity was '\%, factor II determined with 
snake venom was 31%). 
The therapy consisted of vitamin «1 (1 mg), injected twice intrave­
nously. 
Cerebral CT-scan revealed blood in both occipital ventricular horns. 
The diagnosis was vitamin K-dependent intracranial bleeding in a boy 
with alpha-1-antitrypsin deficiency, type ZZ, without a clear liver 
function disorder. After two years the patient shows no apparent se­
quelae. 
The data of the other seven patients are summarized in table 3-1. 
None of the infants received vitamin К prophylaxis at birth. All in­
fants were exclusively breast-fed. Haemorrhage was observed in the 
first week of life or later. Some haemorrhages were relatively small 
like epistaxis or gastro-intestinal haemorrhage. However, serious in­
tracerebral haemorrhages also occurred. Once the haemorrhagic tendency 
was discovered during preoperative coagulation screening. Co-existing 
disease such as malabsorption or liver function disturbance had cer­
tainly contributed to the coagulation disorders in some patients. 
3.2 PATIENTS FROM THE LITERATURE 
Many patients comparable to those in our series were described in 
the literature. Like our patients some had underlying disorders, ma­
king them susceptible to vitamin K-dependent haemorrhage. Alpha-1-ап-
titrypsin deficiency is well known to cause a bleeding tendency in the 
newborn (2, 3, 4, 5, 6). Cystic fibrosis is accompanied by malabsorp-
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tion and vitamin К deficiency (7, θ, 9, 10, 11), even beyond the neo­
natal period. Haemorrhage is an important problem in patients with bi­
liary atresia (12), as it is in the uncommon autosomal recessive dis­
order a-beta-lipoproteinemia (13). Vitamin К deficiency is sometimes 
related to medication. Anticonvulsive drugs can cause vitamin К defi­
ciency in neonates and older infants (14), especially if taken by the 
mother during pregnancy (15, 16, 17, 18). Oral supplementation of vi­
tamin К to the pregnant epileptic mother seems to prevent bleeding 
disorders in their infants (19). Drugs interfering with the vitamin К 
cycle can produce severe bleeding. In the literature, salicylate (20, 
21, 22) and cephalosporins with N-methyl-thio-tetrazole side chain 
(23, 24, 24, 26) are mentioned, although there are no reports yet 
about bleeding in neonates caused by these drugs. 
The literature contains an even larger number of reports on vitamin 
K-dependent bleeding episodes in neonates without obvious disease or 
medication. Breast-feeding apparently plays a role in these cases. Hu­
man milk contains a mean concentration of 2.1 ug/L vitamin K-) (27), 
while cow's milk has a concentration of vitamin K-j four times higher 
and in the commonly used formula in the Netherlands (Almiron ) it is 
as high as 50 pg/L. With the exception of four, no infant described in 
the literature with vitamin K-dependent haemorrhage had received vita­
min К prophylaxis at birth. Large numbers of patients were described 
from far-eastern countries like Thailand (28, 29), Taiwan (30) and Ja­
pan (31, 32, 33). A survey by a study group of the Japanese ministry 
of Health and Welfare revealed that in Japan the incidence of vitamin 
К dependent-haemorrhage is 1:1700 in breast-fed infants and that 81.2л 
of those had intracranial haemorrhage (31). Matsuzaka (33) reported an 
average incidence of intracranial haemorrhage in Nagasaki City of 1:-
1500 in exclusively breast-fed infants. He reviewed all cases of in­
tracranial haemorrhage over a six year period. From a group of 20 in­
fants with intracranial haemorrhage from unknown causes, 16 cases were 
assumed to be caused by vitamin К deficiency. All of these 16 cases 
met the following conditions: (a) they were all breast-fed infants, 
(b) the haemorrhage occurred suddenly in the period from two weeks to 
three months after birth, (c) they had either acute or subacute intra­
cranial haemorrhage which was diagnosed by lumbar puncture, subdural 
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puncture, brain CT-scanning or open-skull surgery, (d) they demonstra­
ted either haemorrhagic diathesis such as purpura, haematemesis, mele­
na or prolonged blood coagulation or multifocal intracranial hemorrha­
ge, (e) haemorrhagic diathesis was controlled by vitamin К administra­
tion. Nagao et al. (33) reported 425 infants with vitamin K-dependent 
bleeding episodes seen during a three year period (197B-1980) in Ja­
pan. In 91 of these vitamin К deficiency could be assumed to be secon­
dary to specific disorders such as congenital bile duct atresia, chro­
nic diarrhea and others. In the other 334 infants vitamin К deficiency 
was idiopathic; however, all of them were excusively (2Θ6) or partial­
ly (48) breast-fed. Intracranial haemorrhage was seen in 290 infants 
(875ί). None of them had received vitamin К at birth. In western coun­
tries the incidence of vitamin К deficiency with haemorrhage in 
breast-fed infants with or without vitamin К prophylaxis at birth is 
unknown. McNinch et al. (34) reported six cases of haemorrhagic disea­
se out of 7000 deliveries during a 17 month-period in Devon (United 
Kingdom), which would represent an incidence of 1:1200 (34). Sporadic 
cases were reported from the United States of America (35, 36, 37, 
38), the United Kingdom (34, 39, 40, 41, 42, 43), France (44), New 
Zealand (45) the Federal Republic of Germany (46,47 48) and Switzer­
land (49). In total, 454 exclusively breast-fed and 58 partially 
breast-fed infants were reported. Of these 512, 432 had intracranial 
haemorrhage (84.4%). Mortality is not reported by all authors, but the 
overall mortality rate from reported cases is 35.5% (36/102). It is 
striking to observe vitamin K-dependent haemorrhage in four patients 
who received vitamin К prophylaxis at birth: Chaou et al (30) reported 
a breast-fed infant, five months old, with intracranial haemorrhage, 
who received vitamin К at birth. The child also had Hirschprung's 
disease. Verity et al (50) reported 3 infants who received 1 mg of vi­
tamin К at birth, but developed intracranial bleeding secondary to vi­
tamin К deficiency at the age of 4, 6 and 7 weeks respectively. The 
type of feeding was not mentioned. One of them had biliary atresia. 
It is quite clear from the data presented here that vitamin К defi­
ciency resulting in haemorrhage may occur in otherwise healthy neona­
tes. Sometimes an underlying disorder is present. We observed 10 cases 
during a three-year period. 
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Vitamin K-dependent haemorrhage should be prevented. One dose of 1 
mg of vitamin К by intramuscular injection at birth will reduce the 
number of cases significantly, but will not eradicate vitamin К defi­
ciency completely as shown by the findings of Verity et al. (50) and 
our own study (chapter 7). Some infants apparently need supplementa­
tion of vitamin К beyond the early neonatal period. 
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CHAPTER 4 
BIOCHEMICAL VITAMIN К DEFICIENCY IN EARLY INFANCY: DIAGNOSTIC LIMITA-
TATION OF CONVENTIONAL COAGULATION TESTS. 
J. Widdershoven, L. Kollée, P. van Munster, Α.-M. Bosman, L. Monnens. 
Department of Pediatrics, University of Nijmegen, St. Radboud Hospi­
tal, Nijmegen, The Netherlands. 
Helv. paediat. Acta 1986; 41: 195-201. 
4.1 SUMMARY 
Thrombotest, factor II and factor X determinations were performed 
in two groups of children, one receiving a low vitamin К diet (breast­
feeding) and one receiving a high vitamin К regimen (formula-fee­
ding). No infant received vitamin К at birth. Thrombotest values were 
found to be lower at day 30, 60 and 90 after birth, and factor II le­
vels unexpectedly higher at day 30 and day 60 in the breast-feeding 
group compared to the formula-feeding group. No difference in factor X 
levels could be detected. Compared to the direct measurement of PIVKA 
II by a highly sensitive immunological method, these coagulation tests 
are inadequate to detect biochemical vitamin К deficiency. 
4.1 ZUSAMMENFASSUNG 
Thrombotest-, Faktor-II- und Faktor-X-Bestimmungen wurden bei zwei 
Gruppen von Säuglingen durchgeführt: Die einen erhielten eine vitamin-
K-arme (Muttermilch), die anderen eine vitamin-K-reiche Nahrung (Fla-
schenmilch). Keines der Kinder bekam eine Vitamin-K-Prophylaxe bei der 
Geburt. Thrombotestwerte waren am 30., 60. und 90. Tag niedriger, Fak-
tor-II-Werte am 30. und 60. Tag jedoch unerwartet höher bei den ge-
stillten als bei den flaschenernährten Säuglingen. Die Faktor-X-
Bestimmung zeigte keinen Unterschied zwischen den beiden Gruppen. Im 
Vergleich zur direkten Messung von PIVKA II mit einer sehr sensiblen 
immunologischen Methode sind die in dieser Studie durchgeführten kon-
ventionellen Bestimmungen zum Nachweis eines biochemischen Vitamin-K-
Mangels ungeeignet. 
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4.1 RéSUMé 
Thrombotest, Facteur II et facteur X ont été mesurés chez deux 
groupes d'enfants, les uns nourris au sein (pauvre en vitamine Κ), les 
autres nourris au lait artificiel (enrichi en vitamine K). Aucun des 
enfants n'a reçu une prophylaxie de vitamine к après la naissance. 
Chez les enfants nourris au sein, les valeurs du thrombotest ont été 
trouvées plus basses à l'âge de 30, 60 et 90 jours, les taux du 
facteur II par contre plus élevés, un résultat inattendu. Il n'existe 
pas de différence du facteur X entre les deux groupes. Les tests de 
coagulation conventioneis pour déceler un déficit biochimique en 
vitamine К sont donc inférieurs à la méthode immunologique très 
sensible de détermination de PIVKA II. 
4.2 INTRODUCTION 
Vitamin К dependent hemorrhage is reported to occur in exclusively 
breast-fed infants (5, 7, 9). The low vitamin K-| content of human milk 
(2.1 μg/L) is considered to be an important factor in this vitamin К 
deficiency state (3). Infant formulas commonly used in the Netherlands 
contain at least 50 pg/L of vitamin K-|. 
Vitamin К is required for the modification and activation of the 
clotting profactors II, VII, IX and X. These factors are synthetised 
in the liver, containing 10 glutamic acid residues at the amino 
terminal part of the molecule. Posttranslational carboxylation of 
glutamic acid (Glu) to gamma-carboxy-glutamic acid (Gla), in which 
vitamin К is an obligatory со-factor, creates effective calcium 
binding sites on these proteins. The non-carboxylated proteins are 
called PIVKA's (protein induced by vitamin К deficiency). In vitamin К 
deficiency not only PIVKA but also other coagulation abnormalities can 
be observed (Table 4-1). 
The aim of this study was to investigate whether there was a 
difference in the vitamin К dependent coagulation, studied in the 
conventional way, between breast-fed infants (low vitamin К intake) 
and formula-fed infants (high vitamin К intake). The results of the 
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conventional blood coagulation test are compared to the presence of 
PIVKA II in the blood of the same infants. 
The study was approved by the local ethical committee. 
Increased PT (prothrombin time) 
Increased PTT (partial thromboplastin time) 
Decreased thrombotest value or normotest value 
Decreased coagulation activity of factors II, VII, IX and X 
The presence of PIVKA (protein induced by vitamin К absence) 
Table 1. Possible abnormalities in vitamin К deficiency. 
4.3 MATERIALS AND METHODS 
Blood was collected on days 4, 30, 60 and 90 from exclusively 
breast-fed (n=78) or bottle-fed (n=36) infants. Two milliliters of 
blood was drawn by venipuncture and collected in plastic tubes con­
taining one part of sodium citrate to nine parts of blood and 1% tra-
sylol (10,000 KIE/mL). All infants were born after uneventful pregnan­
cy between 37 and 42 weeks of gestational age; the apgar score was 
more than 7 and the arterial pH more than 7.20. None of the infants 
was dysmature (weight under Ρ 2.3). None of the infants received vita­
min К prophylaxis at birth. 
The following determinations were performed: 1. Thrombotest© (Ny-
gaard); 2. Factor X, activated by Russell's viper venom and calcium, 
the formed factor X
a
 was measured by using the chromogenic substrate 
S2337 (KabiVitrum); 3. Factor II (X
a
PC) activated by the physiological 
activators V, X
a
, calcium and phospholipid; factor II (ECar), activa­
ted by vipers' venom of the Echis Carinatus snake. The formed thrombin 
in both factor II determinations was measured by using chromogenic 
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substrate S223B (KabiVitrum). A factor II(X
a
PC)/factor II (ECar) ratio 
lower than 0.Θ6 indicates the presence of acarboxy factor II (1). 
PIVKA II was measured by an ELISA using a monoclonal antibody against 
abnormal decarboxylated prothrombin (6). Factor II (X
a
PC), factor II 
(ECar) and factor X were selected because they can be measured in 
small quantities of blood with chromogenic substrate. 
To compare the results obtained in both groups of infants Wilcox-
on's two sample test was used. Some infants dropped out of the study 
population because the parents refused further co-operation or the 
mother stopped breast-feeding. When not enough blood was obtained, not 
all tests were performed. 
4.4 RESULTS 
Factor X levels were not different in both groups (Table 4-2). Four 
days after birth a level of about 40% of the adult values is reached, 
rising to about 70л at the age of three months. The results of factor 
II determination by a physiological activation (X
a
PC) are shown in ta­
ble 4-3, and those of factor II determination by activation with vi­
pers' venom (ECar) in table 4-4. Because the latter measures both fac­
tor II and non-carboxylated factor II (PIVKA II), a clear difference, 
defined as a ratio X
a
PC/ECar<0.66, between the outcome of both deter­
minations indicates vitamin К deficiency. From the results shown in 
tables 4-3 and 4-4 such a difference cannot be demonstrated. From day 
4 up to day 90 an increase in factor II levels of about 20SÓ was found 
to occur. On the fourth day there was no difference in factor II level 
between the breast-fed and bottle-fed infants, whatever the method 
used. On day 30 and 60 the level of factor II measured by both me-
thods, was significantly higher in breast-fed infants notwithstanding 
their lower vitamin К intake. At the age of 90 days we did not find a 
statistically significant difference between both groups. At the 
fourth day the thrombotest revealed no difference between both groups 
(table 4-5). The succeeding determinations showed a statistically 
significant lower value in breast-fed infants. Bottle-fed infants 
showed a more pronounced increase in thrombotest values than 
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Day Breast-fed infants Bottle-fed infants 
4 
30 
60 
90 
η 
76 
53 
34 
23 
mean 
42.2 
59.1 
64.2 
68.5 
SD 
6.4 
8.7 
12.6 
12.8 
η 
36 
27 
19 
13 
mean 
43.1 
60.5 
62.9 
69.5 
SD 
7.0 
11.4 
10.2 
11.5 
ρ-value 
0.73 NS 
0.46 NS 
0.84 NS 
0.96 NS 
Table 4-2. Factor X levels in breast-fed and bottle-fed infants at 4, 
30, 60 and 90 days of age 
π = number of samples investigated; SD = standard deviation 
NS = not significant. Factor X values are expressed as a 
percentage of an adult plasma pool. 
Day Breast-fed infants Bottle-fed infants 
η mean SD η mean SD p-Value 
4 51 48.0 8.1 23 45.1 8.0 0.17 NS 
30 32 56.5 8.9 19 48.5 6.2 0.001 S 
60 16 68.0 11.7 9 54.2 9.1 0.01 S 
90 12 71.9 11.1 7 64.9 11.4 0.12 NS 
Table 4-3. Factor II (X
a
PC) measured with physiological activators in 
breast-fed and bottle-fed infants at 4, 30, 60 and 90 days 
of age 
Factor II values are expressed as a percentage of a normal 
adult plasma pool. 
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Day Breast-fed infants Bottle-fed infants 
η mean SD η mean SD p-Value 
4 55 49.6 8.1 23 46.9 7.7 0.15 NS 
30 32 58.4 8.9 19 50.3 6.1 0.001 S 
60 18 67.6 12.1 9 55.5 9.6 0.01 S 
90 12 73.9 10.4 7 66.7 9.9 0.12 NS 
Table 4-4. Factor II (ЕСаг) measured with snake venom in breast-fed 
and bottle-fed infants at 4, 30, 60 and 90 days of age 
Factor II values are expressed as a percentage of a normal 
adult plasma pool. 
Day Breast-fed infants Bottle-fed infants p-Value 
η mean SD η mean SD p-Value 
4 78 38.2 12.6 35 39.9 13.1 0.67 NS 
30 62 75.5 18.7 32 90.0 16.2 0.0002 S 
60 62 77.8 18.1 27 93.4 10.7 0.0002 S 
90 34 78.7 17.3 23 89.4 15.3 0.02 S 
Table 4-5. Thrombotest values in breast-fed and bottle-fed infants at 
4, 30, 60 and 90 days of age 
Thrombotest values are expressed as percentage according to 
the directions for use. 
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C h i l d PIVKA TT F a c t o r I I FX Q Day Feeding 
X
a
PC ECar 
дм Q/ о/ o/ V 
H U /о /о /о /О 
19 
194 
220 
234 
251 
252 
262 
280 
2Θ1 
332 
432 
439 
143 
164 
181 
475 
442 
450 
0.30 
0.35 
0.23 
1.50 
0.90 
0.35 
0.30 
0.25 
0.35 
0.73 
1.90 
1.30 
0.27 
0.18 
0.32 
4.50 
1.00 
0.52 
39 
30 
52 
48 
32 
38 
26 
37 
-
45 
66 
60 
94 
100 
59 
39 
63 
84 
49.7 
40.7 
39.6 
55.4 
50.7 
42.8 
29.6 
52.8 
-
62.7 
50.3 
38.1 
68.2 
64.3 
73.7 
71.0 
89.2 
_ 
51.3 
47.8 
42.1 
56.7 
52.1 
44.7 
31.1 
55.4 
-
66.1 
52.2 
40.2 
68.6 
65.7 
74.6 
78.7 
92.0 
_ 
36 
40 
47 
46 
44 
39 
41 
44 
-
48 
53 
51 
74 
65 
49 
59 
81 
65 
0.97 
0.85 
0.94 
0.98 
0.97 
0.96 
0.95 
0.95 
-
0.95 
0.96 
0.95 
0.99 
0.98 
0.99 
0.90 
0.97 
_ 
4 
4 
4 
4 
4 
4 
4 
4 
4 
30 
30 
30 
60 
60 
60 
60 
90 
90 
breast 
bottle 
bottle 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
breast 
Table 4-6. Infants in which PIVKA II was detected in our study popula­
tion. 
PIVKA II values expressed in arbitrary units (AU)/mL, 1 AU 
corresponding with 1 ¡jq of purified prothrombin. TT = 
Thrombotest. Factor II XaPC = factor II measured with phy-
siological activators; factor II ECar = factor II measured 
with snake venom. FX = factor X. Q = quotient XaPC/ECar. 
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breast-fed infants, an increase which occurred between day 4 and day 
30. 
In 18 infants reported in an earlier paper, the presence of PIVKA 
II was demonstrated (table 4-6) (13). Values for thrombotest, factor 
II, factor X of these infants were not significantly different from 
their age-matched controls in this study. PIVKA II was not detectable 
by the method of Bertina et al. (1) in these children except for one 
(child number 194). 
4.5 DISCUSSION 
Information on conventional blood-coagulation tests in normal in­
fants receiving no vitamin К prophylaxis after birth on different fee­
ding regimen up to the age of three months is not yet available. Mos­
sel et al. (В) measured factors I, II, VIII, IX, X and XI in four in­
fants receiving vitamin К and seven not receiving vitamin К after 
birth. The measurements were performed in cord blood as well as in 
blood collected between 2-4 days of age. They found the values of vi­
tamin К dependent coagulation factors II, IX and X to be higher in the 
second blood sample in the children receiving vitamin К prophylaxis. 
In our study we found no difference in coagulation tests between in­
fants on a low or high vitamin К diet on the fourth day of life. 
Jürgens et al. (4) measured factors I, II, V and VII in cord 
blood. They concluded that cord blood was not convenient for coagula-
tion studies because of a mild form of disseminated intravascular coa-
gulation occurring during delivery. 
Jiménez et al. (3) performed coagulation studies on one-month-old 
infants, one group fed cows' milk and one group exclusively breast-
fed. All infants received 1 mg of vitamin К intramuscularly. 
Normotest and thrombotest values were statistically significantly 
prolonged in the breast-feeding group (12). Prothrombin time, activa­
ted partial thromboplastin time, factor II values, factor VII values, 
factor IX values and factor X values showed no difference between both 
groups. In our study we found the same results for the thrombotest and 
factor X determination in children not receiving vitamin К prophylaxis 
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at birth. The factor II levels, however, were higher in the breast­
feeding group in our study at one month of age. 
Peters et al. (10) measured factor X, activated by Russell's viper 
venom, on the seventh day of life in two groups of infants; one group 
received vitamin К intramuscularly after birth. They found no diffe­
rence between both groups. In our study no difference in factor X le­
vel between infants on low or high vitamin К diet was found. Factor X 
levels, measured in this way is not dependent on the vitamin К status 
in newborn infants. 
In our study factor X activity was equal in both groups. Factor II 
activity, however, was high in breast-fed infants at 30 and 60 days 
after birth although they received less vitamin К in their feeding; 
this finding is as yet unexplained. 
We were unable to demonstrate the presence of PIVKA II by the X
a
PC/ 
ECar ratio (1) in all but one child (child number 194). The thrombo-
test values of breast-fed infants showed lower values at 30, 60 and 90 
days after birth. Not all the factors determining the thrombotest va­
lues were measured in our study. The thrombotest value depends on the 
activity of factor II, factor VII and factor X and the presence of 
PIVKA (13), and it is therefore difficult to explain these findings. A 
lower value of factor VII activity, or the presence of PIVKA's of fac­
tor VII or X are a possible explanation. 
In an earlier paper (13), the presence of PIVKA II was reported in 
18 infants of this study-population after the age of four days by the 
very sensitive method of Motohara et al. (6). The thrombotest, factor 
X, factor II-X
a
PC, factor II ECar and the ratio X
a
PC/ECar, however, in 
these infants were not statistically different from the control values 
as shown in table 4-6. 
Our conclusion is that conventional blood coagulation tests are not 
sensitive enough to demonstrate a biochemical vitamin К deficiency. A 
biochemical vitamin К deficiency mostly has no clinical consequences, 
but it indicates how delicate the balance is between bleeding tendency 
and coagulation in these children. An additional burden, however, can 
induce severe bleeding in these infants. 
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5.1 ABSTRACT 
Protein С antigen levels were measured in the plasma of healthy 
full term infants by electroimmunoassay. During the first three months 
of life (on day four, at one month, two months and three months of 
age) protein С antigen levels were compared in breast-fed and bottle-
fed infants. None of the two groups of infants received vitamin К at 
birth. Only at the age of three months there was a significant diffe­
rence between the groups. Unexpectedly infants, who were breast-fed, 
had a higher protein С level at three months of age. Levels were also 
measured in 15 healthy children between one and three years of age. 
The antigen levels increase with age to reach adult values at about 
three years of age. 
5.2 INTRODUCTION 
An increased incidence of hemorrhage due to vitamin К deficiency is 
reported in breast-fed infants (9). This deficiency is due to the li­
mited intake of vitamin K-]. Mature human milk from lactating mothers 
has a mean concentration of vitamin K-j of 2.1 pq/L (7). Commercial 
formulas in the Netherlands contain at least 50 ug K-|/L. Whether the 
intestinal flora of the breast-fed infant produces less endogenous vi­
tamin К than the flora of the formula-fed infant is unknown. The clas­
sic way of demonstrating vitamin К deficiency consists of measuring 
the vitamin К dependent clotting factors (factors II, VII, IX and X). 
This method, however, is not suitable for an assessment of a mild vi­
tamin К deficiency (9). 
The vitamin К dependent coagulation factor proenzymes contain 
γ-carboxyglutamic acid formed by posttranslational action of vitamin К 
dependent γ-glutamylcarboxylase (5). Except for the classical vitamin 
К dependent factors (F.II, VII, IX and X), a number of other proteins 
contain γ-carboxyglutamic residues and are for their synthesis in the 
liver dependent on vitamin K, one of these is protein С (15). This vi­
tamin К dependent plasma zymogen is activated by thrombin in the pre­
sence of thrombomodulin (2). Activated protein С functions as an anti-
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coagulant by inactivating factors V
a
 and VIII
a
 (2) and stimulating fi­
brinolysis (3). Because the half life of protein С is remarkably shor­
ter (6 to 8 hours, similar to factor VII) than that of factors II, IX 
and X the measurement of the protein С level in plasma could be a sen­
sitive technique to reveal a transient deficiency of vitamin К (6). 
The aim of this study is to report the protein С levels in infant 
breast-fed or bottle-fed during the first three months of life and to 
present normal values for protein С antigen during infancy and early 
childhood. 
5.3 SUBJECTS AND METHODS 
Studies were performed in healthy full-term infants. None of them 
received vitamin К intramuscularly at birth. Blood was collected for 
protein С measurements on day four and at one, two and three months of 
age. 
On day four 56 breast-fed infants were studied. Blood was collected 
from the same infants at the above mentioned later dates under condi­
tion that they were still breast-fed. The number of infants who were 
bottle-fed (Almiron M2® ) was 24 on day four. A decreasing number of 
the same infants was studied at one, two and three months of age. Pro­
tein С antigen was assayed by electroimmunoassay as described by Ber-
tina at al. (1). The protein С antigen was also measured in 15 normal 
infants older than three months up to the age of three years in order 
to follow the development of plasma protein С antigen levels. 
For statistical analysis, the Wilcoxon's rank sum test was used to 
compare the breast-fed and bottle-fed infants. Because of the diffe­
rence between breast-fed and bottle-fed infants at the age of three 
months, normal values were calculated for both groups separately. From 
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normal values for protein С ( b r e a s t f e e d i n g ) 
(%) 
7 0 -
6 0 -
5 0 -
4 0 -
30-
2 0 
10-
alarm 
l imit 
warning 
l i m i t 
mean 
warning 
limit 
alarm 
limit 
—ι 1 1 1 1 1 1 — 
θ 9 10 11 12 13 14 
-ι 1 г-
2 3 4 
- ι — 
7 weeks 
Fig. 5-1. Normal values for protein С in breast-fed infants under 
three months of age. η = 53. (One measurement a child). 
Expected protein С antigen concentration = 30.2 + 14.0 
1_e-0.0191xage in days
 # M e a n i s t h e e X p e c t e d value. Low 
values: A5 = -15.6, W5 = -Θ.6. High values: A95 = +33.9, W95 
= +11.0. 
A = alarm limit. W = warning limit. 
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normal values for protein С ( bottle feeding ) 
(«v.) 
120-
100-
8 0 -
6 0 -
4 0 -
2 0 -
alarm 
l imit 
_ warning 
l i m i t 
mean 
warning 
l imit 
alarm 
l i m i t 
3 6 9 12 15 18 21 24 27 3 0 33 month 
Fig. 5-2. Normal values for protein С in bottle-fed infants, η = 59. 
(One measurement a child). Expected protein С antigen con­
centration = 31.θ + 82.3 i_e-Û.0014xage in days
 # Mean is 
the expected value. Low values: A5 = -23.1, W5 = -12.9. 
High values: A95 = +33.1, W95 = +14.8. 
A = alarm limit. W = warning limit. 
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all infants just one measurement was chosen at random. The way of fee­
ding at that moment indicated the group of that infant. As protein С 
values increase with age and a constant level is reached for adults 
the following model was thought reasonable: 
Protein С = α + Q П-е(^ х ад е)] 
The parameters a, G and γ were estimated by nonlinear regression, whe­
re α indicates the level at age 0 and « + G the level for adults; γ 
is the time-constant. 
Normal order statistics on the residuals, i.e. the difference be­
tween the measured value and the value according to the fitted model, 
were applied to find 90&-confidence intervals for the fifth and nine­
ty-fifth percentiles. Boundaries are indicated with W (for Warning) 
and A (for Alarm) as at least 5% of the population will be beyond W 
and at the most 55a beyond A. These intervals were superimposed on the 
fitted model (Fig. 5-1 and Fig. 5-2). 
5.4 RESULTS 
The results of plasma protein С antigen measurement during the 
first three months of life in bottle-fed and breast-fed infants are 
presented in table 5-1. Normal values for protein С in breast-fed in­
fants up to three months of age are presented in Fig. 5-1. In Fig. 5-2 
results are presented for bottle-fed infants up to three years of 
age. The protein С antigen level increases during the first three 
months of life. The Wilcoxon's rank sum test showed no statistical 
difference between breast-fed and bottle-fed infants at the age of 
four days, one month and two months. When they were three months old, 
the breast-fed infants had a significantly higher level of protein С 
antigen. According to the fitted model adult values are presumably 
reached when children are 3 years old. The adult values measured in 33 
healthy individuals showed a mean value of 9θ?ό with a standard devia­
tion of 19%. 
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5.5 DISCUSSION 
Although protein С levels, because of the short half-time of this 
protein, should be a good tool to reveal a transient deficiency of vi­
tamin K, it was not possible to show significantly lower protein С an­
tigen levels in breast-fed infants at the age of four days, one, two 
and three months. The plasma protein С level in the breast-fed infants 
compared to the bottle-fed infants (p = 0.013) showed an unexplained 
higher concentration (table 5-1). The ages were selected in order to 
enable us to detect classic hemorrhagic disease of the newborn, occur­
ring at two to five days of age and late hemorrhagic disease, typical­
ly occurring between one and three months of age (2). Protein С measu­
rement does not give the clue whether there is vitamin К deficiency in 
sucklings or not. More specific tests are required to demonstrate vi­
tamin К deficiency, such as the measurement of abnormal, noncarboxyla-
ted prothrombin by enzyme-Iinked sandwich immuno-assay, using a mono­
clonal antibody against this abnormal prothrombin (11, 12). Determina­
tion of the concentration of other precursor proteins (PIVKA-IX, -X, 
-VII) by specific antibodies could give additional information (10, 
14). 
In the immunological assay both fully carboxylated protein С and 
subcarboxylated protein С (PIVKA's) are measured. Part of the protein 
С levels, especially in breast-fed infants, could be subcarboxylated 
protein C. Using two-dimensional Immunoelectrophoresis, however, 
Polack et al. were unable to detect subcarboxylated forms of protein С 
in cord blood (13). The concentrations of protein С measured in our 
group of children are in good agreement with the results reported by 
Schettini et al. (14) in full term newborns during the first year of 
life and with the results reported by Polack et al. (13) in cord 
blood. In contrast to the findings of Schettini et al. (14), however, 
we found that adult values were only reached at 3 years of age and not 
between the 6th and 9th month of age. This may be explained by the 
greater number of infants and children in the present study. The in­
crease of the protein С antigen concentration with age, illustrates 
the delicate balance between coagulation factors and their inhibitors 
in infancy. In adults a protein С antigen concentration lower than 60% 
73 
is associated with a history of deep vein thrombosis (Θ). 
Age 4 days 1 month 2 months 3 months 
Breast-fed 
infants 
Bottle-fed 
infants 
Number 
Mean 
SD 
Number 
Mean 
SD 
56 
32.4Й 
10.2 
24 
30.95Í 
10.4 
44 
39.7% 
11.3 
23 
35% 
11.7 
31 
3B.53Í 
7.6 
1B 
33.7% 
Θ.3 
20 
48.6% 
9.5 
13 
40.8% 
7.5 
p-value 0.46 0.07 0.09 0.013 
Table 5-1. Plasma protein С antigen levels during the first 3 months 
of life. All measurements. 
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CHAPTER 6 
INFLUENCE OF THE TYPE OF FEEDING ON THE PRESENCE OF PIVKA-II IN IN-
FANTS. 
J. Widdershoven1, K. Motohara2, F. Endo2, I. Matauda2, L. Monnens1, 
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 Department of Pediatrics, University of Nijmegen, The Netherlands 
2
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6.1 SUMMARY 
PIVKA-H levels were studied by a highly sensitive immunological 
method in two groups of infants, breast-fed and bottle-fed, at the age 
of 4 days, 1 month, 2 months and 3 months. РІ КА-П could be demon­
strated in 9 infants after the age of 1 month when they were breast­
fed. In none of the bottle-fed infants PIVKA-II was present during the 
same period. This significant difference can probably be explained by 
the lower vitamin Κι content of human milk compared to commercial for­
mulas. The frequently occurring biochemical deficiency of vitamin К 
indicates the need of prophylactic administration of vitamin К to all 
newborns. 
6.1 ZUSAMMENFASSUNG 
Der PIVKA-II-Gehalt des Blutes wurde mit einer hochempfindlichen 
immunologischen Methode bei zwei Gruppen von Säuglingen, nämlich voll 
gestillten und mit der Flasche ernährten, bestimmt, und zwar im Alter 
von 4 Tagen sowie von einem, zwei und drei Monaten. PIVKA-II konnte im 
Alter über einem Monat bei neun gestillten und bei keinem künstlich 
ernährten Säugling nachgewiesen werden. Dieser signifikante Unter-
schied kann wahrscheinlich durch den geringeren Vitamin-K-Gehalt der 
Frauenmilch im Vergleich zu den kommerziellen Milchpräparaten erklärt 
werden. Der häufig auftretende biochemische Vitamin-K-Mangel weist auf 
die Notwendigkeit einer Vitamin-K-Prophylaxe für alle Neugeborenen 
hin. 
6.1 RéSUMé 
Le taux sanguin de PIVKA-II a été déterminé par une méthode immuno-
logique très sensible chez deux groupes d'enfants. Des enfants nourris 
au sein et des enfants à l'allaitement artificiel ont été étu-diés à 
l'âge de 4 jours, un mois, deux mois et trois mois. PIVKA-II a 
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été démontré chez neuf enfants nourris au sein après l'âge d'un mois, 
mais chez aucun des enfants à l'allaitement artificiel. Cette diffé-
rence significative peut être expliquée probablement par le taux bas 
de vitamine К dans le lait maternel en comparaison avec des aliments 
artificiels. La fréquence du déficit biochimique en vitamine К montre 
la nécessité d'une prophylaxie de vitamine К pour tous les nouveau-
nés. 
6.2 INTRODUCTION 
Although considerable progress has been made in the understanding 
of the role of vitamin К in early infancy, routine prophylaxis is 
still challenged. The necessity of prophylaxis is dependent on the 
frequency of vitamin К deficiency in infancy. 
In the presence of vitamin K, glutamic acids at the amino-terminal 
part of the precursors of the coagulation proteins are carboxylated to 
gamma-carboxyglutamic acid in a posttranslational reaction. The adja­
cent carboxyl groups of gamma-carboxyglutamic acid residues provide 
the vitamin K-dependent proteins with characteristic calcium and 
phospholipid-binding properties essential for their function. 
Several laboratory methods are available for the demonstration of 
vitamin К deficiency by measuring these abnormal, non-carboxylated co­
agulation factors or PIVKA's (protein induced by vitamin К absence). 
The immunological procedure (PIVKA-II), however, is the most specific 
and sensitive method to assess the vitamin К status. PIVKA-II is the 
circulating prothrombine precursor induced by vitamin К deficiency. 
The aim of this report is to present data about the presence of PIVKA-
II in two groups of children (breast-fed and bottle-fed) without admi­
nistration of vitamin К at birth. 
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6.3 SUBJECTS AND METHODS 
The subjects were grouped as follows: 
- Group I: healthy full-term infants, who were exclusively breast-fed 
during the period studied. Blood was collected at 4 days, 1 month, 
2 months and 3 months. When breast-feeding was stopped, blood was no 
longer collected. 
- Group II: healthy full-term infants who received commercial formulas 
mostly Almiron M2· Blood was collected at the same time-schedule. 
One milliliter of citrated blood was obtained by venipuncture of each 
infant. One part of sodium citrate 3.8% was added to nine parts of 
blood. After centrifugation, the plasma was stored at -70°C. The 
plasma was transported to Japan on dry ice. The PIVKA-II level was de­
termined by an enzyme-linked immunosorbent assay, using a monoclonal 
antibody as previously described (6). This antibody reacts with abnor­
mal prothrombin (decarboxylated prothrombin) quantitatively and does 
not cross-react with native prothrombin. In normal adults, PIVKA-II 
was absent (below 0.13 AU/mL). In severe vitamin К deficiency observed 
in Japan, plasma PIVKA-II is above 40 AU/mL. 
6.4 RESULTS 
The results are presented in table 6-1 and table 6-2. On the fourth 
day of life PIVKA-II could be demonstrated in 9 of 129 infants, 7 of 
them in the breast-fed and two in the bottle-fed group. After 1 month 
PIVKA-II was only seen in the group of breast-fed infants. The diffe­
rence between both groups at day 4 is not significant. When we compare 
all infants studied at one, two and three months of age, who keep the 
same type of feeding, the breast infants had a significantly higher 
presence of PIVKA-II than the bottle-fed infants (Fisher's exact test 
ρ = 0.027). In none of the infants the level of PIVKA was higher than 
40 AU/L, the level observed in severe vitamin К deficiency. 
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Days after birth 
4 30 60 90 
Group I Number of infants 77 62 44 33 
(breast-fed) PIVKA-II present 7 3 4 2 
Group II Number of infants 36 43 48 45 
(bottle-fed) PIVKA-II present 2 0 0 0 
Table 6-1. Presence of PIVKA-II in two groups of infants. 
Days after birth 
4 30 60 90 
Group I 0.25 0.30 0.30 0.35 0.73 1.90 0.27 0.18 1.00 
(breast-fed) 0.35 0.90 1.50 1.30 0.32 4.50 0.52 
Group II 0.35 0.23 -
(bottle-fed) 
Table 6-2. Level of PIVKA-II in infants studied. 
PIVKA-II levels are expressed in AU/mL. 
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6.5 DISCUSSION 
Vitamin K-deficient hemorrhage in infancy occurs during three pe­
riods in infancy: 0 to 24 hours, 1 to 7 days and 1 to 3 months of li­
fe. Only during the two later periods vitamin К administration at 
birth can have a preventive effect (4). 
By selecting 4 days, one, two and three months after birth as the 
time of blood collection, we will have an idea of the frequency of 
biochemical vitamin К deficiency during these critical periods. 
Vitamin K-dependent coagulation factor proenzymes (factor II, VII, 
IX, X, protein C, protein S) contain gamma-carboxyglutamic acid formed 
by posttranslational action of vitamin K-dependent gamma-glutamylcar-
boxylase. These residues of gamma-carboxyglutamic acid confer to the 
coagulation factors the capacity to bind to phospholipid surfaces in 
the presence of calcium. This binding is essential for physiologic 
activation of these factors (2). Abnormal prothrombin (undercarboxyla-
ted) can be detected by a specific monoclonal antibody with a highly 
sensitive method (6). 
It can be argued that the immaturity of the carboxylase system in 
the liver, rather than vitamin К deficiency, explains the abnormal 
prothrombin levels in our group of infants. This is highly improbable, 
as it does not account for the difference between breast-fed and 
bottle-fed infants. As the vitamin К content of mature human milk gi­
ves a mean concentration of 2,1 \ig/l (3), and the commercial formulas 
in the Netherlands contain at least 50 μς/1, there is an important 
difference in source of vitamin К immediately after birth. In Japan, 
treatment by a single oral dose of 5 mg vitamin К at birth diminished 
significantly the incidence of PIVKA-II positive newborns at 3 and 5 
days (7). 
Our own group of breast-fed children treated with vitamin К at 
birth is yet too small to allow statistical calculations. Studies 
about this aspect are in progress. 
The biochemical evidence of vitamin К deficiency in our infants 
supports the need for general vitamin К administration after birth not 
only to premature but also to all full-term infants. The optimal dose, 
time and route of supplementation should*be further studied. 
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Although clinically evident vitamin К deficiency in normal circum­
stances may be rare (5), a small additional burden during infancy may 
cause severe clinical vitamin К deficiency. Case reports in the lite­
rature illustrate this clearly, e.g. maternal convulsants (9), liver 
function disturbances such as biliary atresia (10), alpha-1-antitryp-
sine deficiency (8), and administration of Cephalosporine (1). 
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CHAPTER 7 
PLASMA CONCENTRATIONS OF VITAMIN «1 AND PIVKA-II IN BOTTLE-FED AND 
BREAST-FED INFANTS WITH AND WITHOUT VITAMIN К PROPHYLAXIS AT BIRTH. 
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7.1 SUMMARY 
Plasma vitamin K-) and PIVKA-II were assayed simultaneously at 1-4 
days and at 29-35 days after delivery in three groups of infants: 
breast-fed not receiving vitamin К at birth (n=12), bottle-fed without 
vitamin К administration at birth (n=7) and breast-fed with one mg vi­
tamin Ki administered by intramuscular injection at birth (n=13). The 
bottle-fed infants had a significantly higher vitamin K-| level in 
plasma than breast-fed infants when both did not receive vitamin K-) at 
birth. After intramuscular administration of vitamin К extremely high 
values were obtained 1-4 days later. At the age of one month breast­
fed infants had the same concentration of vitamin K-) wether or not 
they received vitamin K-|. PIVKA-II, a reliable indicator of biochemi­
cal vitamin К deficiency, was present in 5 out of 12 breast-fed and 2 
out of 6 bottle-fed infants without supplemental vitamin K-| after 
birth. 
In a separate study a larger group of breast-fed infants without 
extra vitamin К had a significantly higher presence of PIVKA-II in 
plasma than bottle-fed infants without extra vitamin K-). These data 
form a strong argument for the routine vitamin К prophylaxis after 
birth of all breast-fed infants. The optimum dose and manner of admi­
nistration require further study. 
7.2 INTRODUCTION 
Vitamin К is essential for the activity of prothrombin, factor VII, 
IX, X, protein С and protein S. In the presence of vitamin K, glutamic 
acid-residues at the amino-terminal part of the precursors of these 
coagulation proteins are carboxylated to gamma-carboxy-glutamic acid 
in a posttranslational reaction. The adjacent carboxyl groups of gam­
ma-carboxy-glutamic acid-residues provide the vitamin К dependent pro­
teins with characteristic calcium and phospholipid binding properties 
that are essential for their function. In vitamin К deficiency, ab­
normal, des-carboxylated, coagulation factors appear, known as PIVKAs 
(Proteins Induced by Vitamin К Absence). Vitamin К dependent bleeding 
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is reported in young infants. These bleedings are sub-devided in early 
(within 24 hours), classic (between 2 and 5 days after birth) and 
late-onset (after 1 month of age) haemorrhagic disease of the new­
born. Breast-feeding has a role in classic and late-onset haemorrhagic 
disease (1). 
Human milk contains a mean value of 2.1 pg/L vitamin K-| (2), while 
formula most frequently used in the Netherlands (Almiron®) contains 50 
fjg/L. In an earlier study, PIVKA-II could be demonstrated in 9 out of 
62 breast-fed infants after the age of one month. In none of the bott­
le-fed infants was PIVKA-II present over the same period (3). 
The aim of this study is to present combined data on the levels of vi-
tanin Ki and PIVKA-II in cord blood and in three groups of infants, 
bottle-fed and breast-fed with and without vitamin К prophylaxis at 
the age of four days and after one month. The prophylactic effect of 
intramuscular injection of one mg vitamin К after birth, which is re­
commended by the American Academy of Pediatrics (4), was evaluated in 
breast-fed infants up until! the age of three month. 
7.3 SUBJECTS AND METHODS 
The infants from whom blood was collected for vitamin K-) determina­
tion were divided into three groups. The first group (n=12) was 
breast-fed not receiving vitamin К at birth. The second group was 
bottle-fed (n=7), not receiving vitamin К at birth. The third group 
was breast-fed (n=13) receiving one mg of vitamin К (Konakion®) by 
intramuscular injection at birth. All infants were delivered vaginally 
after an uneventful pregnancy. Blood for vitamin K-] determination was 
collected at day one to four days and at 29 to 35 days after delive­
ry. In addition cord blood was collected (n=16). Five milliliters of 
blood were drawn by venipuncture, centrifugated and stored at -20°C in 
the dark. Vitamin K-| levels were measured using HPLC with post-column 
reaction and fluorescence detection as previously described (5). 
In all samples assayed for vitamin K<| PIVKA-II was also measured, by 
an enzyme-linked immunosorbent assay using a monoclonal antibody as 
previous described (6). This antibody reacts with abnormal prothrombin 
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Figure 7-1: Vitamin «1 levels shortly after birth and after one month 
of age in bottle-fed infants without vitamin К prophylaxis (a), 
breast-fed infants without vitamin К prophylaxis (b) and breast-fed 
infants with vitamin К prophylaxis at birth (c). The dotted line 
presents the detection limit. 
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(descarboxylated prothrombin) quantitatively and does not cross react 
with native prothrombin. PIVKA-II was absent in healthy adults (^О.ІЗ 
AU/mL). In severe vitamin К deficiency observed in Japan, PIVKA-II was 
above 20 AU/mL. 
PIVKA-II determinations were also performed in blood collected in 
breast-fed infants (n=61), receiving one mg of vitamin К by intramus­
cular injection at birth. This study supplements an earlier study 
(3). Citrated blood was drawn by venipuncture at four, 30, 60 and 90 
days after birth. 
To allow correct interpretation of the PIVKA-II levels measured, a 
knowledge of the half-life of PIVKA-II is required; PIVKA-II was the­
refore measured in five healthy adults on anticoagulant treatment for 
thrombosis prevention. The day after discontinuing warfarin they re­
ceived two doses of 10 mg vitamin K-) orally with a twelve hours inter­
val!. PIVKA-II was measured while the subjects were taking warfarin, 
four hours after the second administration of 10 mg vitamin K-] and 
three, seven, 14 and 28 days later. 
For statistical calculations Fisher's exact-test was used. 
Informed consent was obtained from all parents and from the adult pa­
tients. The study was approved by the local ethical committee. 
7.4 RESULTS 
The results of vitamin K-i measurement are presented in Table 7-1 
and figure 7-1. In cord blood vitamin K·) levels are under the detec­
tion limit (<70 pg/mL). After birth there is a steep rise in vitamin 
K-) levels in bottle-fed infants already in the first few days, related 
to the increase in feeding volume (fig. 7-1 A).Breast-fed infants, how­
ever, have a rather low level in the first few days of life, with a 
moderate rise in most cases at one month of age (fig.7-1B). Bottle-fed 
infants have higher levels in the first few days of life (p=0.07) and 
even significantly higher vitamin K·] levels after one month (p=0.0017) 
than breast-fed infants without vitamin К prophylaxis at birth. 
Breast-fed infants receiving one mg of vitamin K-j by intramuscular 
injection at birth have extremely high levels shortly after birth 
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B o t t l e - f e d (no v i t К) 
Breast-fed (no v i t К) 12 
Breast-fed ( v i t К ) 
1-4 days 
η mean 
7 1595 
378 
13 32711 
median 
1688 
237 
29722 
SD 
1269 
370 
25375 
η 
6 
12 
9 
mean 
2890 
707 
698 
29-35 
median 
3119 
445 
470 
days 
SD 
633 
747 
536 
Table 7 - 1 : Vitamin K-) levels i n b o t t l e - f e d and breast-fed i n f a n t s w i t h 
and without v i tamin К prophylaxis at b i r t h . 
Vitamin Ki levels are expressed in pg/mL. 
SD=standard d e v i a t i o n . 
cord-blood 
Breast-fed (no vit К) 
Bottle-fed (no vit К) 
day 
0 
0 
0 
0 
0 
2 
3 
4 
4 
5 
1 
3 
PIVKA-II 
0.22 AU/mL 
0.60 AU/mL 
1.99 AU/mL 
3.32 AU/mL 
3.57 AU/mL 
0.37 AU/mL 
6.14 AU/mL 
7.64 AU/mL 
13.94 AU/mL 
0.45 AU/mL 
0.23 AU/mL 
0.86 AU/mL 
vitamin K-| levels 
<70 pg/mL 
<70 pg/mL 
<Г70 pg/mL 
<70 pg/mL 
<70 pg/mL 
208 pg/mL 
431 pg/mL 
266 pg/mL 
<140 pg/mL 
<350 pg/mL 
< 350 pg/mL 
927 pg/mL 
Table 7-2: PIVKA-II levels and corresponding vitamin K-) levels measu­
red in the same sample. The differences in detection limit 
are caused by differences in plasma volume. 
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(fig. 7-1C). At one month of age the vitamin K-) levels of breast-fed 
infants receiving vitamin К prophylaxis are in the range of the levels 
in breast-fed infants without vitamin К prophylaxis. 
The results of PIVKA-II measurement in samples in which vitamin K·) 
was also determined are presented in Table 7-2 and compared to the vi­
tamin K-j levels. In cord blood PIVKA-II was detected in five out of 
16 samples, while in all samples, as mentioned before, vitamin K-) was 
under the detection limit. In breast-fed infants not receiving vitamin 
К prophylaxis, PIVKA-II was detected in five out of 12 samples, drawn 
at three to five days after birth. After one month no PIVKA-II was 
found in this small group (n=12). In bottle-fed infants aged one to 
three days, PIVKA-II was detected in two out of seven infants; after 
one month no PIVKA-II was detected in this small group (n=6). In the 
group of infants receiving one mg vitamin K-j at birth no PIVKA-II was 
detected in the samples (n=13) used for vitamin Κι measurement. There 
is no correlation between PIVKA-II levels and vitamin K-| levels (Table 
7-2). 
The results of PIVKA-II measurement over a longer period of time in 
breast-fed infants, receiving one mg of vitamin K-i by intramuscular 
injection at birth, are presented in Table 7-3 and Table 7-4. For 
these infants no information is available on vitamin К-] serum levels. 
The results in this group are compared to previously published 
findings for bottle-fed infants and breast-fed infants without vitamin 
К prophylaxis at birth, published before (3). The number of infants 
studied, however, has now been enlarged. At day four there is no 
difference between the three groups. After the first month of life, 
bottle fed infants have significantly less PIVKA-II present compared 
with breast-fed infants without vitamin К prophylaxis (Fisher's exact 
test p=0.005). Moreover breast-fed infants with vitamin К prophylaxis 
seem to have less PIVKA-II than those without prophylaxis, though not 
significantly less (Fisher's exact test p=0.10). We detected PIVKA-II 
after the age of one month in two infants with vitamin К prophylaxis; 
one infant was two months old, the other three months. The levels of 
PIVKA-II detected are presented in Table 7-4. 
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days after birth 4* 30 60 90 
Bottle-fed (no vit К) 4(43) 0(49) 0(48) 0(52) 
Breast-fed (no vit К) 11(93) 4(73) 4(44) 3(40V 
Breast-fed ( vit К ) 5(61) 0(48) 1(29) 1(23) 
Table 7-3: PIVKA-II detected O0.13 AU/ml) in bottle-fed and breast­
fed infants with and without vitamin К prophylaxis at 
birth. Number of infants between parentheses. 
Fisher's exact test: * : Not Significant 
** : p=0.005 
*»*: p=0.10 
Days a f t e r b i r t h 30 60 90 
B o t t l e - f e d 0.23 0.23 0.35 0.86 
(no v i t К) 
Breast-fed 0.25 0.30 0.30 0.35 
(no v i t К) 0.35 0.45 0.90 1.50 
6.14 7.64 13.94 
0.37 0.73 0.18 0.27 0.52 
1.30 1.90 0.32 4.50 1.00 
3.82 
Breast-fed 
( vit К ) 
0.23 0.43 0.45 0.48 
1.46 
0.25 0.32 
Table 7-4: Level of PIVKA-II i n bott le-Fed and breast-fed i n f a n t s w i t h 
and without v i tamin К prophylaxis at b i r t h . PIVKA-II levels 
are expressed i n AU/mL. 
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The r e s u l t s of consecutive Р1 КА-П measurement i n adul ts d i s c o n t i ­
nuing warfar ins and supplemented w i t h vitamin K-) y i e l d a h a l f - l i f e of 
PIVKA-II of about 2.4 days ( f i g 7 - 2 ) . 
log Pivka-ll 
log AU/ml 
Ì 
1-
- 1 J 
Figure 7-2: PIVKA-II levels in adult patients discontinuing couma-
rins. The second measurement is performed after the administration of 
20 mg vitamin K-| orally. 
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7.5 DISCUSSION 
The undetectable vitamin K-| levels in cord blood are in agreement 
with the results of Shearer et al. and reflect the low placental 
transfer of vitamin К (7, 8). 
The human fetal liver stores of vitamin K-| are about one-fifth of 
those of older children and adults (7). Information about vitamin Ki 
levels in infants not receiving vitamin К prophylaxis is limited. In 
infants with a post-natal age of one to six hours Sann et al. found a 
mean vitamin Ki concentration of 9 pg/L (9000pg/mL) (9). 
The interference of coextracted lipids of the biologic matrix, how­
ever, hampers the use of high performance liquid chromathography with 
absorption detection. The levels in adults measured with our method 
are in the same range as those reported by Hart et al. and Langenberg 
et al. as opposed to the higher values reported by Lefevere et al. and 
Sann et al. (5). 
McNinch et al. reported vitamin K-| levels in breast-fed infants re­
ceiving one mg of vitamin K-| either at birth (orally or by intramuscu­
lar injection) or with the first feed (orally) (10). In conformity 
with their results the serum levels obtained in our study after intra­
muscular administration of one mg of vitamin K-j are extremely high, 
that is to say about 100 times the normal adult values at one to four 
days after birth. It is striking that at the age of one month the 
plasma levels of vitamin K-] in breast-fed infants with or without vi­
tamin K-| prophylaxis were about the same. The higher intake of vitamin 
«1 in bottle-fed infants is reflected in a higher vitamin K-) level in 
plasma. When compared with normal adult values bottle-fed infants pro­
bably obtain an excess of vitamin K-) in their formula. 
Motahara et al. using the same method as we did found PIVKA-II 
circulating in 21.5% of 51 newborns cord-blood samples(11). At three 
to five days of age 50 to 60% of the infants studied, were PIVKA-II 
positive when breast-fed and not receiving vitamin К at birth. In our 
study in five out of 16 newborns PIVKA-II was present in cord-blood. 
At the fourth day of life PIVKA-II could be demonstrated in plasma in 
only 11 out of 93 cases. It would be important to compare the vitamin 
1 content of breast milk in Japanese and Dutch women. 
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At first sight one would expect to find an inverse correlation be­
tween PIVKA-II and Vitamin K-| levels. The biological half-life of 
PIVKA-II, however, should be taken into consideration. We found a 
half-life of PIVKA-II of 2.4 days in adults discontinuing coumanns. 
Motohara found a half-life of about 20 hours in Vitamin К deficient 
infants who were suppleted with 5 mg Vitamin K2 orally or 1-2 mg Vita­
min K2 parenterally (12). It is clear that the presence of PIVKA-II is 
a reliable indicator of Vitamin К deficiency. But PIVKA-II can still 
be present in plasma when the deficiency of Vitamin K-) has already 
been supplemented. This might explain the occurrence of PIVKA-II 2-5 
days after birth, when the Vitamin K-) level in breast-fed infants had 
already reached an adult level (Table 7-2). 
It is an astonishing fact that some infants are vitamin К deficient 
at birth,although the PIVKA-II levels do not indicate a severe defi­
ciency. To prevent haemorrhage it is advisable to shorten this period 
of deficiency. Because of its lower vitamin K-] content breast-milk is 
not as suitable as commercial formulas. Routine prophylaxis should be 
given to all breast-fed infants at birth. The optimum dose and manner 
of administration need to be determined. Even after receiving vitamin 
К prophylaxis at birth, PIVKA-II was present in one infant at 60 days 
and in one infant at 90 days after birth. 
Verity et al. presented 3 infants with the late form of haemorrha-
gic disease of the newborn (4, 6 and 7 weeks after birth) who had re­
ceived one mg of vitamin К at birth (13). 
Probably due to the wide variation in Vitamin К content of breast-
milk, some breast-fed infants need a supplement of vitamin K-] beyond 
the neonatal period in order to prevent Vitamin К dependent haemorrha­
ge. 
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CHAPTER θ 
GENERAL DISCUSSION - SUMMARY. 
Although administration of vitamin К for prevention of haemorragic 
disease of the newborn is a well-known medical practice, discussion 
about this subject continues. Some authors wonder whether vitamin К 
deficiency occurs in the newborn, while others are convinced that 
vitamin К deficiency is real. Göbel et al. (1), Mori et al. (2) and 
Malia et al. (3) found no evidence of vitamin К deficiency by 
maesuring vitamin К dependent coagulation factors in preterm and term 
infants receiving breast-milk or formula, with and without vitamin К 
prophylaxis. Motohara et al. (4) detected circulating PIVKA-II in 21 
out of 99 Japanese newborns indicating vitamin К deficiency. It is 
extremely important to use an adequate method to establish vitamin К 
deficiency state. An insensitive technique can lead to false 
conclusions. Using two dimensional crossed-immuno-electrophoresis with 
rabbit antibodies against prothrombin in a medium containing 2 mmol/L 
calcium lactate, van Doorm et al. (5) concluded that healthy babies 
are not likely to have vitamin К deficiency. The number of 
investigated infants however was not mentioned. Using the sensitive 
method developed by Motohara et al. (6) we found circulating PIVKA-II 
in cord blood of 5 out of 16 healthy Dutch newborns (chapter 7) 
indicating vitamin К deficiency. 
In the second chapter some current methods to detect circulating 
abnormal prothrombin are evaluated. This des-carboxylated abnormal 
prothrombin occurring in vitamin К deficiency is called PIVKA (Protein 
Induced by Vitamin К Absence). The detection of PIVKA-II by the EIA, 
developed by Motohara et al. (6) is a sensitive and reliable indicator 
for biochemical vitamin К deficiency. Other methods separating PIVKA-
II and prothrombin electrophoretically or measuring PIVKA-II by use of 
snake venom adsorption to BaSO^ or measuring prothrombin by use of its 
physiological activators in comparison to total factor Π including 
PIVKA-II by use of snake venom, are less sensitive, more time consu­
ming and even can give false positive results. For the correct inter­
pretation of the results of PIVKA-II measurement the half-life of this 
abnormal prothrombin has to be taken into account. We studied the 
half-life in adults, who discontinued oral anti-coagulants and recei­
ved vitamin K. In this way we estimated the half-life of PIVKA-II to 
be about 2.4 days (chapter 7). But it is unknown whether the effect of 
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anticoagulants in the liver is immediately stopped by this procedure. 
Japanese collegues studied the half-life in vitamin К deficient in­
fants receiving vitamin К suppletion; they found the half-life of 
РІ КА-П to be 20 to 30 hours (7). Probably the latter estimation is a 
better and more physiological approach. 
Conventional coagulation tests like the thrombotest or the determi­
nation of vitamin К dependent coagulation factors or the determination 
of the vitamin К dependent protein С are not adequate to detect a bio­
chemical vitamin К deficiency (chapters 4 and 5)(8, 9). 
Studies on vitamin К deficiency in infancy require a specific me­
thod to measure vitamin К in small quantities of plasma. In coopera­
tion with the laboratory for medical biochemistry and clinical analy­
sis of the faculty of farmaceutical sciences in Ghent (Belgium) vita­
min «1 levels were determined in cord blood, in serum from newborns 
and in serum from one month old infants using HPLC with post-column 
reaction and fluorescence detection (10). The validity of the vitamin 
K·] determinations has been extensively discussed by Lefevere in his 
thesis (11), and more recently by Lambert et al. (10). According to 
them the interference of coextracted lipids of the biological matrix 
together with the extremely low levels of vitamin K-| hamper the use of 
high performance liquid chromatography with absorption detection. A 
serious gain in sensitivity can be obtained by amperometric or coulo-
metric reoxidation of the formed hydroxyquinone but this procedure is 
unsuitable on a routine basis. As an alternative they describe a HPLC 
separation followed by a post column reduction with a knitted open tu­
bular reactor and with tetramethylammonium octahydridotriborate as a 
reagent. The reduced form (quinol) of vitamin K-| so formed, is 
measured by fluorescence detection. The use of an internal standard 
was found to be desirable. From the preliminary results presented by 
McCarthy we know that vitamin K2 is not detectable in fetuses or 
neonates until about 14 days post-partum (12). 
By use of the ELISA on PIVKA-II (6) a biochemical vitamin К defici­
ency was detected in four days old infants (chapter 6). Information 
about vitamin K-) levels in these infants were not available. The bio-
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chemical vitamin К deficiency as indicated by the presence of PIVKA-II 
in these infants was absent in bottle-fed infants of one, two and 
three months of age, while breast-fed infants still were prone to vi­
tamin К deficiency. The results of the studies on the vitamin К status 
at birth are puzzling; undetectable vitamin К levels were found by us 
in cord blood (n=16) while PIVKA-II was only present in five of these 
samples. Apparently enough vitamin K-) is present in liver tissue to 
permit a normal formation of prothrombin in most of them. In the in­
fants studied the PIVKA-II levels in cord blood were low and not in 
the range causing severe clinical deficiency. Motohara et al. (4) re­
ported corresponding results. He found PIVKA-II in 21 out of 99 in­
fants but the levels of PIVKA-II did not exceed 2,0 AU/mL. In Dutch 
infants receiving vitamin К fortified formula, vitamin К deficiency 
could not be detected after the first few days of life. Plasma vitamin 
К-) levels in breast-fed infants show a very wide range, but the mean 
values are higher than in normal adults (chapter 7 ) . In bottle fed in­
fants high levels are reached; the levels are four times higher than 
adult values and could indicate an overdose in these infants. After 
intramuscular injection of vitamin K-) extremely high levels are reach­
ed, about 100 times the normal adult value (chapter 7) (10). Adverse 
effects of these extremely high levels in infants are as yet unknown. 
Human milk contains less vitamin K-| (14) than formula-feeding and 
gives insufficient protection against biochemical and clinical vitamin 
К deficiency (chapters 6 and 7) (13). The administration of one mg of 
vitamin K-) by intramuscular injection to the newborn causes extremely 
high plasma levels of vitamin K-| shortly after birth, but after one 
month plasma levels of vitamin K-) do not differ significantly between 
breast-fed infants receiving vitanin К prophylaxis and those not re­
ceiving prophylaxis. Intramuscular injection of vitamin К at birth did 
not prevent the recurrence of PIVKA-II in breast-fed infants, as low 
levels of PIVKA-II were detected in one two-months old infant (n=29) 
and one three-months old infant (n=29). McCarthy et al. (12) reported 
preliminary results that higher than normal hepatic levels of vitamin 
K-] in the liver may be maintained for several weeks after birth after 
intramuscular injection, but the type of feeding was not mentioned. 
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Although vitamin К deficiency and vitamin К dependent haemorrhage 
is a problem in early infancy (chapter 3), the incidence of vitamin К 
dependent haemorrhage in the Netherlands is unknown. Biochemical vita­
min К deficiency, detected by the presence of PIVKA-II is frequently 
occurring in breast-fed infants. We found PIVKA-II to be present in 23 
of 250 samples taken of breast-fed infants (9.2515) (chapter 7). From 
the University Hospital of Nijmegen 10 cases of vitamin К dependent 
haemorrhage were reported in a 3 years period. In the Nijmegen area 
about 80.000 infants are born during this period resulting in an inci­
dence of reported vitamin К dependent haemorrhage of 1:8000. 
The sensitive method to measure PIVKA-II and the recently developed 
method to measure vitamin Κι provide us with the tools for further 
study. Oral administration of vitamin K·) (15) as reported by McNinch 
et al. is practical, but further study is needed to establish the dai­
ly requirement and the duration of supplementation. The daily dose of 
extra vitamin K-) should be high enough to protect also children with 
mild liver function disorders or absorption disturbances. Motohara et 
al. (16) evaluated the effect of the oral administration of 5 mg vita­
min K2 at birth and after 14 days. All infants were breast-fed. They 
were randomly divided into three groups. Group 1 (n=171) did not re­
ceive vitamin K. Group 2 (n=112) received 5 mg vitamin K2 orally at 
birth. In group 3 (n=B9) 5 mg vitamin K2 was administered twice - at 
birth and 14 days after birth. PIVKA-II was measured at one month of 
age. In group 1 PIVKA-II was found in 21 out of 171 infants (mean 
PIVKA-II level 1.46 AU/mL). In group 2 PIVKA-II was found in 19 out of 
95 infants (mean PIVKA-II level 0.96 AU/mL). In group 3 PIVKA-II was 
found in 3 out of 95 infants (mean PIVKA-II level 0.32 AU/mL). 
An overview about the results of PIVKA-II measurements indicating 
biochemical vitamin К deficiency and the effect of the type of feeding 
and vitamin К prophylaxis is given in table Θ-1. 
A still unsolved question is whether administration of vitamin К 
to the mother before delivery can prevent or should prevent the pre­
sence of PIVKA-II in cord-blood. 
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Source prophylaxis type of cord-
feeding blood 
3th day 4th day 5th day 1 mnth 2 mnth 3 mnth 
Motohara no breast 21(99) 16(26) 
(4) 5 mg K2 orally breast 5(27) 
Widders- no 
hoven no 
(Chapter 7) 1 mg К·) i.m. 
bottle 
breast 
breast 
Motohara no breast 
(16) 5 mg «2 orally breast 
2 times 5 mg K2 orally breast 
(at birth and after 2 weeks) 
5(16) 4(43) 
12(93) 
5(61) 
27(51) 
4(35) 
0(49) 
4(73) 
0(48) 
21(171) 
19(95) 
3(89) 
0(48) 
4(44) 
1(29) 
0(52) 
3(40) 
1(23) 
Table 8-1: The presence of P1VKA-1I in different groups of infants varying in age, vitamin К 
prophylaxis and type of feeding. Number of infants between parentheses. 
The role of vitamin К in coagulation is well established. Vitamin К is 
a co-enzyme involved in the conversion of glutamic acid residues 
(Glu) into gamma carboxy glutamic acid residues (Gla). The Gla contai­
ning coagulation factors II, VII, IX and X and the coagulation inhibi­
ting proteins С and S are mentioned in this thesis. During the last 
ten years several other vitamin К dependent proteins are discovered 
like osteocalcin, urinary Gla-protein and sperm Gla-protein; moreover 
vitamin К dependent carboxylase was demonstrated in the microsomal 
fractions of allmost all tissues (16). Knowledge about the function of 
these proteins and the vitamin К dependent carboxylase system could 
provide us with a new insight in the function of vitamin K. Osteocal­
cin is the vitamin К dependent calcium binding protein of bone matrix 
containing three gamma-carboxy glutamic acid (Gla) residues. The bio­
logical function is unknown, but it probably plays an important role 
in bone-metabolism and mineralisation. In the concluding remarks of 
his recent overview on osteocalcin Hauschka (18) mentioned a variety 
of interesting properties of osteocalcin including: 1) a specific Gla-
dependent binding of Ca2+ ions and adsorption to hydroxy apatite; 2) 
Ca2+-induced transition to alpha-helical conformation accompanied by 
increasing affinity for hydroxyapatite; 3) Mg2+ antagonism of hydroxy-
apatatite binding; 4) interference with brushite-hydroxyapatite meta­
morphosis and hydroxyapatite formation; 5) biosynthesis by osteoblast-
like cells, stimulated by vitamin D; 6) appearance in bone with the 
onset of mineralization; 7) low levels circulating in blood and varia­
tions with age, sex, time of the day and bone pathology; Θ) accumula­
tion in sites of ectopic calcification; 9) chemoattractant activity 
toward human peripheral monocytes which can transform into osteo­
clasts; and 10) competitive inhibition of leucocyte elastase. 
The possible importance of vitamin К in bone metabolism is illustrated 
Hart et al. (19) who detected depressed levels of vitamin K·] in osteo­
porosis. 
Urinary Gla-containing protein is a glycoprotein identified in human 
urine, it requires the presence of gammacarboxy glutamic acid for its 
activity. It is designated by Nakagawa et al. (20) as glycoprotein 
crystalization inhibitor (GCI) and it has a inhibitory effect on the 
precipitation of various calcium salts. The concentration of human 
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urinary Gla protein GCI in human urine (16 mg/L) із well above the 
concentration required for the in vitro inhibition of calcium-salt 
precipitation (21). Vitamin К antagonists possibly interfere with the 
function of GCI. Fowler et al. (22) suggested a lithogenic effect in 
patients using oral anticoagulants. 
The function of the sperm Gla protein (SGP) is still unknown (22). In 
a recent overview Vermeer (17) showed that almost all tissues contain 
vitamin К dependent carboxylase, but the proteins carboxylated by 
these enzymes are not yet identified except for the ones already men­
tioned. 
The study of the role of vitamin К in the human being is a promising 
area of research. 
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SAMENVATTING 
Dit proefschrift is gewijd aan vitamine К deficiëntie bij zuigelin-
gen. Bij de aanvang van de studie was de gangbare mening dat vitamine 
К deficiëntie bij de "normale" pasgeborene niet voorkwam. Patiënten 
met hersenbloedingen als gevolg van vitamine К tekort, opgenomen in 
het Academisch Ziekenhuis te Nijmegen, deden echter anders vermoeden. 
Al deze patiënten werden uitsluitend met moedermelk gevoed; moedermelk 
bevat slechts weinig vitamine К in vergelijking tot de gebruikelijke 
Nederlandse kunstvoedingen. De werkgroep "Vitamine K" werd opgericht 
om de frequentie van vitamine К deficiëntie vast te stellen en onder-
zoek te verrichten naar de preventie van de vaak ernstige bloedingen 
die het gevolg hiervan kunnen zijn. 
In hoofdstuk 1 wordt de rol van vitamine К in de bloedstolling be­
sproken en voorts het voorkomen van vitamine К in de voeding, de ver­
deling van de bloedingen naar tijdstip van optreden, de behandeling 
van een deficiëntie en de huidige controverse over vitamine К profyla-
xe. 
Gezocht werd naar een gevoelige en betrouwbare methode om een bio­
chemisch tekort aan te tonen voordat een manifeste bloedingsneiging 
tot uiting komt. De verschillende methoden om de abnormale stollings-
factoren die in bloed verschijnen bij vitamine К tekort (PIVKA's = 
Protein Induced by Vitamin К Absence) te bepalen, worden geëvalueerd. 
De EIA, ontwikkeld door Motohara, is voor ons doel het meest ge-
schikt. Deze EIA maakt gebruik van monoclonale antilichamen gericht 
tegen abnormaal prothrombine (PIVKA-II); met normaal factor-II reage-
ren zij niet (hoofdstuk 2). 
In hoofdstuk 3 worden de patiënten die in Nijmegen werden gezien 
beschreven en tevens wordt een overzicht gegeven van de literatuur 
over patiënten met bloedingen ten gevolge van vitamine К deficiëntie. 
Veel gebruikte laboratoriumtechnieken zoals de bepaling van de 
thrombotest of de bepaling van de spiegels van stollingsfactoren zijn 
ontoereikend om een biochemische vitamine К deficiëntie aan te tonen 
(hoofdstuk 4). 
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Evenmin is de bepaling van proteine С geschikt voor het aantonen 
van een biochemisch vitamin К tekort. Proteine С is een vitamine К af­
hankelijke remmer van de bloedstolling, met een relatief korte half­
waarde tijd (Hoofdstuk 5). 
Met de EIA, gebruikmakend van monoclonale antistoffen tegen PIVKA-
II, werd plasma onderzocht, verkregen van twee groepen zuigelingen 
(borstvoeding en flesvoeding) op de leeftijd van 4, 30, 60 en 90 da­
gen. Geen van de kinderen kreeg vitamine К profylactisch toegediend. 
Na de leeftijd van 1 maand is bij kinderen gevoed met moedermelk sig­
nificant frequenter PIVKA-II aanwezig. Bij kinderen gevoed met fles­
voeding was na de leeftijd van 1 maand geen PIVKA-II aantoonbaar 
(Hoofdstuk 6). 
In hoofdstuk 7 wordt het effect van profylaxe met 1 mg vitamine K, 
intramusculair post partum, beschreven. Deze vorm van profylaxe redu­
ceert de aanwezigheid van PIVKA-II, maar voorkomt biochemische vitami­
ne К deficiëntie bij zuigelingen gevoed met moedermelk niet volledig. 
Voorts werden gegevens gepresenteerd over vitamine К spiegels bij zui­
gelingen gevoed met moedermelk of flesvoeding met en zonder vitamine К 
profylaxe. Vitamine К is in navelstrengbloed niet aantoonbaar. Vitami­
ne К spiegels bij zuigelingen vertonen een grote spreiding; de spie­
gels bij zuigelingen gevoed met moedermelk zijn relatief laag. De 
spiegels bij kinderen gevoed met flesvoeding vertonen een snelle stij­
ging na de geboorte en bereiken een hoog niveau. De injectie van 1 mg 
vitamine К geeft extreem hoge vitamine К spiegels; het effect is na 
een maand echter niet meer zichtbaar in de serumspiegels. 
In de discussie worden de bevindingen samengevat en besproken. Te­
vens wordt de rol van vitamine К afhankelijke proteïnes, niet betrok-
ken bij de bloedstolling, aangeduid. De noodzaak van verder onderzoek 
naar dosering van vitamine К voor de preventie van vitamine К defi­
ciëntie bij zuigelingen gevoed met moedermelk wordt besproken. 
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DANKWOORD 
Mijn dank gaat allereerst uit naar de ouders van de zuigelingen die 
hun medewerking verleenden bij het onderzoek. De gegevens die werden 
verkregen uit de analyses van de bloedmonsters die werden afgenomen 
bij hun kinderen vormen de basis voor dit proefschrift. 
In prettige samenwerking met de kliniek voor verloskunde en gynéco-
logie van het Sint Radboudziekenhuis (Hoofd: Prof. Dr. Т.К.A.B. Eskes) 
werden de ouders van deze kinderen benaderd. 
Alle leden van de werkgroep "Vitamine K" droegen in belangrijke ma­
te bij aan het werk door hun inspiratie en steun, vooral in de moei­
lijke tijd dat ik mijn aandacht moest verdelen tussen Oss en Nijme­
gen. Buiten degenen die op de tweede pagina genoemd worden, zijn dit 
Dr. CG. van Oostrom en Dr. R. de Abreu. Bij de startfase van het on­
derzoek waren Prof. Dr. Т.К.A.B. Eskes, Prof. Dr. C.A.M. Haanen en 
Prof. Dr. H.C. Hemker betrokken. 
Een plezierige gedachtenwisseling over de mogelijkheden tot preven­
tie van vitamine К deficiëntie ontstond met Prof. Dr. G.A. de Jonge 
(Vrije Universiteit Amsterdam) en Dr. H. Wierenga te Assen. 
De laboratoriummedewerkers van het laboratorium voor Kindergenees-
kunde en Chirurgie van het Academisch Ziekenhuis te Nijmegen, Anne-
Mane Bosman, Maria van der Putten-van Meyel en Theo van Lith hebben 
geduldig en nauwgezet alle analyses verricht en de technieken van hun 
haken en ogen ontdaan (Hoofd: Dr. P.J.J. van Munster). 
De samenwerking met Dr. K. Motohara van Kumamoto Universiteit in 
Japan (Hoofd: Prof. Dr. I. Matsuda) voor de PIVKA-II bepaling en de 
samenwerking met Dr. W. Lambert van de Laboratoria voor Medische 
Biochemie en voor Klinische Analyse (Hoofd: Prof. Dr. A. de Leenheer) 
van de Universiteit van Gent voor de Vitamine К bepaling maakte het 
onmogelijke voor ons mogelijk. Aan onze vriendschappelijke contacten 
houd ik prettige herinneringen. 
In de tweede fase van het onderzoek waren de medewerkers van de 
verloskamers (Zr. Bernardette), van de thrombosedienst (Medisch Coör-
dinator: Dr. M.E. Ouwehand) en van het klinisch-chemisch laboratorium 
(Hoofd: Dr. A. Gnbnau) van het St. Anna Ziekenhuis te Oss behulpzaam 
bij het verzamelen van de bloedmonsters. 
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Mijn collega's in Oss, H.L.P. Smeets en J.C.C.J.A. de Vos, namen 
steeds mijn werkzaamheden over als ik hun dit vroeg; hun hulp en inzet 
was onontbeerlijk. Ook de verpleegkundigen in Oss die mijn regelmatige 
afwezigheid moesten accepteren dank ik voor het door hen getoonde 
begrip. 
De statistische bewerking van de in hoofdstuk 4 t/m 7 beschreven 
resultaten was in handen van Dr. H. van Lier en A. de Haan (Mathema-
tisch-Statistische Advies Afdeling). Met name bij de bewerking van 
hoofdstuk 5 hadden zij een centrale plaats. 
De illustraties werden verzorgd door de afdeling Medische Illustra-
tie in samenwerking met de afdeling Medische Fotografie. In tijden van 
nood mocht ik een beroep doen op de medewerkers van de tekenkamer van 
Organon in Oss. 
Marion Titselaar verrichtte snel en accuraat het typewerk voor de 
eerste publicaties. Karin Dingelhoff zette alles nauwgezet op de 
tekstverwerker. 
Tot slot wil ik Guusje bedanken; je nuchtere kijk, de liefde en de 
rust die je mij thuis gaf waren onmisbaar in de achter ons liggende 
periode. Mijn kinderen zullen het allemaal nog niet begrijpen, maar 
hun vader hoopt vanaf nu wat minder vaak te moeten zeggen "even wach-
ten, papa is nu bezig". 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 1 februari 1955 geboren 
in Kerkrade. Hij groeide op in Heerlen. In 1973 behaalde hij het di­
ploma gymnasium Q (R.K. Gymnasium, Sint Bernardinus College, Heer­
len). In hetzelfde jaar begon hij zijn studie in de Geneeskunde aan de 
Katholieke Universiteit te Nijmegen. In maart 197Θ slaagde hij voor 
zijn doctoraal examen, in augustus 1930 werd het artsexamen afgelegd. 
In aansluiting aan de artsenopleiding was hij werkzaam als arts-assi­
stent in opleiding tot kinderarts op de afdeling paediatrie van het 
Sint Radboud Ziekenhuis te Nijmegen (Opleiders: Prof. Dr. E.D.A.M. 
Schretlen en Prof. Dr. G.B.A. Stoelinga). Op 1 september 19B4 werd hij 
als kinderarts ingeschreven in het specialistenregister. Vanaf 1 sep­
tember 1984 tot 1 maart 19Θ5 werkte hij full-time aan het vitamine К 
onderzoek; na 1 maart verrichtte hij part-time onderzoek en was hij 
tevens als algemeen kinderarts werkzaam in het Sint Anna Ziekenhuis te 
Oss. Vanaf 1 januari 1987 werkt hij uitsluitend in laatst genoemd zie­
kenhuis. 
De schrijver is gehuwd en vader van 3 kinderen. 
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Stellingen horend bij het proefschrift "Vitamin К Deficiency in 
Infancy" van J. A. M. Widdershoven. 
1. Bij een zuigeling gevoed met moedermelk en met een bloedingsnei-
ging dient men in de differentieel diagnose steeds te denken aan 
vitamine К deficiëntie als oorzaak, ook als aan dit patientje vi-
tamine К prophylaxe werd gegeven. 
2. Door PIVKA-II meting kan achteraf de diagnose "vitamine К defici­
ëntie" nog gesteld worden, ook als reeds vitamine К aan een 
patient met manifeste bloedingsneiging is toegediend. 
3. Conventioneel stollingsonderzoek schiet tekort bij onderzoek naar 
vitamine К deficiëntie. 
4. De ontwikkeling van de prenatale diagnostiek bij hyperoxalune 
type I, dient met voortvarendheid ter hand genomen te worden. 
5. Bij een kind met buikpijn en hématurie van normaal gevormde ery-
throcyten dient ook aan het zogenaamde "notenkraker syndroom" van 
de vena renalis sinistra gedacht te worden. (Wolfish Ν. M. et 
al. Clin Nephrol. 1985; 26: 96-100.). 
6. Routinematig echografisch onderzoek van de zwangere vóór de twin-
tigste week van de zwangerschap met het doel congenitale (hart-) 
afwijkingen op te sporen, kan grote ethische problemen opleve-
ren voor de aanstaande ouders. 
7. Het aanvragen van specialistisch laboratorium-, rontgen- en 
electro-fysiologisch onderzoek door de eerste lijn maakt de 
gezondheidszorg niet goedkoper, maar levert wel vaak problemen 
op bij de interpretatie van de resultaten van dit onderzoek. 

Hoewel het nadelig effect van passief roken nog niet volledig 
vast staat, zouden zij, die van kinderen houden, niet in hun 
aanwezigheid dienen te roken. (Anonymous. Pediatrics 19Θ6; 77: 
755-757.). 
De adolescent verdient een aparte plaats in het ziekenhuis, 
gezien de bijzondere aard van zijn of haar problemen en het 
groeps-eigen gedrag in de levensfase waarin hij of zij verkeert. 
Een kind met een chronische aandoening zoals bij voorbeeld diabe­
tes, epilepsie of asthma, waarbij zich ernstige complicaties kun­
nen voordoen, dient bij de kinderarts in zijn omgeving bekend te 
zijn in verband met de opvang van deze complicaties. 
De populariteit van alternatieve genezers zegt meer over het 
tekort schieten van de reguliere artsen dan over de werkzaamheid 
van de alternatieve geneeswijzen. 
Regionalisatie van geavanceerde neonatale zorg dient te zijn 
gebaseerd op bidirectionele samenwerking tussen enerzijds de 
kinderartsen en gynecologen in het perifere ziekenhuis en de 
de gynecologen en neonatologen in het perinatologisch centrum 
anderzijds. 
Wanneer bij de huidige bezuinigingen geen rekening wordt gehouden 
met de gedifferentieerdheid binnen de kindergeneeskunde, wordt 
een grove beoordelingsfout gemaakt en dus veel schade aangericht. 
Het gebrek aan parkeerdiscipline bij het sint Anna ziekenhuis in 
Oss kan leiden tot levensgevaarlijke situaties doordat het zie­
kenhuis bij spoed eisende gevallen soms zelfs onbereikbaar wordt 
voor de ambulance of het ziekenhuispersoneel. 



